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ABSTRACT 
In 2013, it was determined by the United States Renal Data System (USRDS) that 32% of 
the people over 60 had some form of chronic kidney disease (CKD)(1). CKD is often age-
associated, but confounding factors make it difficult to separate age-related causes from other 
factors such as diabetes and hypertension. Animal models can be useful to evaluate aging 
nephropathy but are costly since they take years.  The aim of this thesis was two-fold. First, I used 
the Ercc1 deficient mouse model of accelerated aging to test the hypothesis that unrepaired DNA 
damage can cause CKD, similar to that seen as a result of natural aging. Second, I tested the 
hypothesis that inherent podocyte damage due to Ercc1 deficiency causes the loss of kidney 
function associated with aging. In order to test this hypothesis, kidneys from the Ercc1-/∆ mouse, 
a model of a human progeria, and old wildtype (WT) (2-3 yrs) mice were characterized and 
compared to elucidate the time-course and extent of injury. At one month after birth, Ercc1-/∆ mice 
develop evidence of podocyte injury, autophagy induction, and a slightly elevated urine albumin-
creatinine (ACR) ratio. Glomerular filtration rate (GFR) remained comparable to WT mice until 2 
months, after which time albuminuria increased significantly, GFR decreased significantly, and 
podocytes began to display increased IKK expression and chronic NF-κB activation, as seen in 
old WT kidneys. At this same time, increased LC3 and p62 protein levels indicated a functional 
breakdown in autophagy. ICAM up-regulation in glomerular capillaries and tubule apical 
membranes occurred, followed by proximal tubule injury, an increase in myofibroblast-like cells, 
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and macrophage infiltration.  A podocyte specific knock-out of Ercc1 was created and the results 
support the hypothesis that inherent podocyte injury drives age-related kidney pathologies. In 
contrast, a proximal tubule cell specific knock-out of Ercc1 showed no elevation in ACR, and no 
decrease in GFR throughout the time period tested. This thesis provides mechanistic information 
as to how aging nephropathy can occur over time as a result of endogenous DNA damage, and 
provides evidence that the podocyte should be a major target for therapeutic intervention.  
 
 
 
 v 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XIII 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 THE AGING KIDNEY ....................................................................................... 3 
1.1.1 Kidney structure and function ....................................................................... 3 
1.1.2 Podocytes and autophagy ................................................................................ 7 
1.1.3 Changes in human kidney structure and function with aging .................... 9 
1.1.4 Molecular changes that play a role in kidney aging ................................... 11 
1.1.4.1 Calorie restriction extends lifespan and uncovers important 
molecular players for renal aging .................................................................... 12 
1.1.4.2 Modulation of insulin-like growth factor signaling delays aging in the 
kidney 13 
1.1.4.3 Klotho maintains kidney health with age ......................................... 13 
1.1.4.4 Sirtuin1 modulates NF-kB activity and preserves cellular integrity in 
the kidney ........................................................................................................... 14 
1.1.4.5 Longevity factors in the kidney help to reduce oxidative damage and 
preserve autophagy and degradation ............................................................... 15 
1.1.5 Questions that remain ................................................................................... 16 
1.2 ERCC1 MODEL OF ACCELERATED AGING ........................................... 18 
1.2.1 ERCC1-XPF DNA repair enzyme in human health and disease .............. 19 
1.2.2 Ercc1 deficient mouse models. ...................................................................... 20 
1.3 SUMMARY ........................................................................................................ 22 
 vi 
2.0 ACCELERATED RENAL AGING IN THE ERCC1 DEFICIENT MOUSE 
MODEL OF HUMAN PROGERIA .......................................................................................... 24 
2.1 INTRODUCTION ............................................................................................. 25 
2.2 MATERIALS AND METHODS ...................................................................... 27 
2.3 RESULTS ........................................................................................................... 32 
2.3.1 Histopathologic changes in progeroid Ercc1-/Δ mouse kidney mimic normal 
aging 32 
2.3.2 Functional changes in progeroid Ercc1-/Δ mouse kidney mimic normal 
aging 35 
2.3.3 Cellular changes in progeroid Ercc1-/Δ mouse kidney mimic natural aging
 38 
2.3.4 Podocyte effacement in progeroid Ercc1-/Δ and old WT mouse kidney .... 40 
2.3.5 Cell turnover in proximal tubules and collecting ducts of Ercc1-/Δ mice .. 43 
2.3.6 Increased senescence in Ercc1-/Δ and old WT kidney ................................. 46 
2.4 DISCUSSION ..................................................................................................... 51 
3.0 PODOCYTE INJURY CAUSES SUBSEQUENT KIDNEY DISEASE IN ERCC1 
DEFICIENT MOUSE MODEL................................................................................................. 54 
3.1 INTRODUCTION ............................................................................................. 55 
3.1.1 The aging glomerulus .................................................................................... 55 
3.1.2 NF-κB and autophagy ................................................................................... 56 
3.1.3 The Ercc1-/∆ mouse model of accelerated renal aging ................................ 57 
3.2 MATERIALS AND METHODS ...................................................................... 59 
3.3 RESULTS ........................................................................................................... 63 
 vii 
3.3.1 Time course of podocyte injury and age-related kidney pathologies in the 
Ercc1/∆ mouse .............................................................................................................. 63 
3.3.1.1 Age-related chronic NF-κB activation occurs in the podocytes of 
Ercc1/∆ mice ........................................................................................................ 63 
3.3.2 Chronic NF-κB activation onset coincides with autophagic flux impairment 
and induction of kidney pathologies at 2 months .................................................... 70 
3.4 INHERENT PODOCYTE DAMAGE DUE TO ERCC1 DEFICIENCY 
CAUSES SUBSEQUENT TUBULE INJURY, CHRONIC KIDNEY DISEASE, AND 
DECREASED LIFESPAN ................................................................................................. 74 
3.4.1 Functional Changes in Podocyte specific knock-out and Proximal Tubule 
specific knock-out of Ercc1 ........................................................................................ 74 
3.4.2 Ultrastructural changes in Podocyte Specific Knock-out Only ................. 77 
3.4.3 Podocyte knock-out of Ercc1 mirrors age-related cellular changes observed 
in Ercc1-/∆ mouse kidney ............................................................................................ 80 
3.4.3.1 Tubule injury is secondary to inherent podocyte damage .............. 80 
3.4.3.2 Vascular changes, myofibroblast accumulation, and macrophage 
infiltration is caused by Podocyte Ercc1 deficiency ........................................ 82 
3.4.3.3 Ercc1 deficiency in podocytes causes autophagy impairment, chronic 
increase in IKK expression and mTOR activation ......................................... 86 
3.4.4 Crosstalk between IKK-NF-κB and autophagy systems in normal mouse 
podocyte cell line ........................................................................................................ 92 
3.5 DISCUSSION ..................................................................................................... 98 
4.0 SUMMARY AND FUTURE DIRECTIONS ......................................................... 103 
 viii 
4.1 ACKNOWLEDGEMENTS ............................................................................ 110 
APPENDIX A  ........................................................................................................................... 111 
APPENDIX B  ........................................................................................................................... 115 
APPENDIX C ............................................................................................................................ 117 
APPENDIX D ............................................................................................................................ 122 
APPENDIX E  ........................................................................................................................... 123 
BIBLIOGRAPHY ..................................................................................................................... 124 
 ix 
 LIST OF TABLES 
 
Table 1. Summary of Kidney Changes with Aging. ..................................................................... 17 
Table 2. Serum chemistries relevant to renal function ................................................................. 36 
Table 3. Summary of age-related changes in the Ercc1-/∆ kidney. ............................................... 73 
Table 4. List of abbreviations ..................................................................................................... 114 
Table 5. Gene information from transcriptional analysis of Ercc1-/∆ and WT kidneys(131) ..... 121 
 x 
LIST OF FIGURES 
 
Figure 1. ESRD is largely a condition of the aged population ....................................................... 2 
Figure 2. The kidney nephron ......................................................................................................... 4 
Figure 3. The Kidney Filtration Barrier .......................................................................................... 6 
Figure 4. Lifespan of Ercc1 Mouse Models ................................................................................. 21 
Figure 5. Histopathological changes in progeroid Ercc1-/Δ and aged WT mouse kidneys ........... 34 
Figure 6. Changes in renal function in Ercc1-/Δ and WT mice with aging ................................... 37 
Figure 7. Cellular changes in progeroid Ercc1-/Δ and aged WT mouse kidneys ........................... 39 
Figure 8. Structural changes in progeroid Ercc1-/Δ and aged WT mouse kidneys ....................... 42 
Figure 9. Increased cell death and turnover in proximal tubules of progeroid Ercc1-/Δ mice ...... 45 
Figure 10. No evidence of apoptotic cells in Ercc1-/∆ kidneys shown by TUNEL stain. ............. 46 
Figure 11. Increased cell senescence in old and progeroid Ercc1-/Δ mouse kidneys. ................... 49 
Figure 12. Senescence-associated-β-galactosidase (SA-β-gal) increase in Ercc1-/∆  Kidneys ..... 50 
Figure 13. Chronic NF-κB activation in podocytes in the Ercc1-/∆ and old WT kidney .............. 65 
Figure 14. Time course of chronic NF-κB activation in podocytes in relation to other changes . 69 
Figure 15. Glomerular autophagy and IKK changes in the Ercc1-/∆ kidney................................. 72 
Figure 16. Podocyte, but not proximal tubule specific knock-out of Ercc1, results in impaired 
kidney Function and decreased lifespan. ...................................................................................... 76 
Figure 17. Ultrastructural evidence of podocyte and tubule injury in the Ercc1-pod-KO ........... 79 
Figure 18. KIM-1 increase indicates tubule injury after 1 month due to podocyte damage......... 81 
 xi 
Figure 19. Early ICAM increase occurs in Ercc1-pod-KO, but not in Ercc1-PT-KO kidneys .... 84 
Figure 20. Dramatic SMA increase and macrophage infiltration at 7 mo in the Ercc1-pod-KO . 86 
Figure 21. Early induction of autophagy followed by autophagy impairment in the Ercc1 deficient 
glomerulus..................................................................................................................................... 88 
Figure 22. Sustained IKK increase and mTOR activation in Ercc1-pod-KO glomeruli .............. 91 
   Figure 23. IKKi inhibition results in less active autophagy in differentiated mouse podocytes 94 
Figure 24. IKK increases autophagy in podocytes ....................................................................... 97 
Figure 25. Quantification of Podocyte Pedicel and GBM Thickening with Age ....................... 115 
Figure 26. LC3 puncta at cell-cell junctions in podocytes. ......................................................... 122 
Figure 27. Accumulation of LC3+p62+ puncta, decreased autophagy in isolated glomeruli from 
old WT mice ............................................................................................................................... 123 
 xii 
PREFACE 
This has been more than just four years of PhD research, teaching, and learning.  My time 
here in the Center for Biologic Imaging in the Cell Biology program at the University of Pittsburgh 
has resulted in me becoming a stronger, healthier, and happier human being. Along with all of the 
members of my committee, for being so supportive and giving such practical and wise advice, I’d 
like to thank a few individuals in particular.  
I thank you, Donna, most of all. You have been my mentor for the last 16 years in many 
ways. You lead by example, with creativity, enthusiasm, determination, and wisdom.  Most 
importantly, you showed me how to be at peace no matter how rough the waves were. We’ve had 
a wild, exciting ride, and I hope it continues. You always made me laugh. You have a knack for 
putting things into perspective, and you shared such a wealth of knowledge about science and life 
in general. All of that has spilled over into other areas of my life… as a mother, a nature lover, a 
biological photographer, a partner in crime, etc. You taught me how to be brave enough to not just 
“get through,” but to dance my way through. I hope to continue to create memories with you and 
enjoy all of the beauty that we’ve both been blessed enough to experience. Thank you.  
To my Wacks (siblings and parents): you are the best family I could ask for. You stood by 
me through many, many tough times in the last decade or so, and I’m so happy to see you still 
standing by me to celebrate better times. We are connected in ways that non-Wacks can’t 
understand, and I’ve learned just how unique this is during my wild 36 years on planet earth. I love 
you all completely and thank you sincerely.  
To Adam: thank you for helping me to tackle things like a champ, take advantage of every 
moment, and love like I never have before. I’m so lucky you came into our lives. You have been 
 xiii 
my rock in the last year, and you have certainly been more than wonderful to Sadie. I am incredibly 
excited to continue down this road with you. Thank you. 
To all of CBI, especially Simon, Claudette, Katy, Jenny Mark, Morgan, Callen, Patricia, 
Lauren…. all of you: you were there every day to lend a hand, encourage me, give me sage advice, 
and make me laugh. Having started my journey at CBI and then stepping out for science and 
teaching adventures at MIT and in Rochester, I really do know just how lucky I was to be 
welcomed back and supported every step of the way.  I’m very thankful to have been able to work 
in the “Disneyworld” of imaging. I literally grew up in your center, Simon! I hope to continue to 
be lucky enough to collaborate with you in any respect, my friends, as I move on. Thank you. 
To Laura: thank you so much for making it possible to study such a valuable model of 
kidney aging, and for continuing to allow that to happen from Florida. I learned so much from 
spending time in your lab here at Pitt, and met some good friends and colleagues along the way. 
Your clever and innovative ways of thinking as a scientist are something I strive to implement in 
my own future career. You always encouraged me to go the distance and so I did! Thank you.   
To my Sadie Rose: Thank you for being such a brave, clever, silly, optimistic, mature, and 
unique daughter. You are always right there by my side, supporting and cheering me on. You 
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1.0  INTRODUCTION 
It is estimated that over 10% of adults and 32.2% of people over 60 in the U.S. have chronic 
kidney disease (CKD)(1, 2). Due to increased lifespan, the number of elderly people (65 years or 
older) is projected to increase from 420 million in 2000 to 550-973 million by 2030(3). As we age, 
our kidney function declines and other age-related diseases such as hypertension and diabetes 
compound the risk of CKD and end-stage renal disease (ESRD) (Figure 1). Medicare expenditure 
in 2011 for CKD patients was over $40 billion(1). It is imperative to learn about the process of 
aging nephropathy to discover preventative measures, better diagnostic tools, and more effective 
therapies. It has been very challenging to study the effects of kidney aging in humans since there 
are often many additional confounding factors and comorbid conditions that contribute to various 
age-related renal pathologies. Animal models have been useful in this respect, but remain costly 
and take years to manifest age-related diseases. As a result, the mechanisms of aging 
nephropathies, as well as the roles that specific kidney cell types play in these processes, remain 
largely unknown.  
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Figure 1. ESRD is largely a condition of the aged population 
Data was extracted from the 2013 USRDS Atlas of CKD and ESRD in order to plot the prevalence of ESRD by age 
categories in the U.S(1).   
 
The goal of this thesis is to utilize an animal model of accelerated aging to elucidate the 
mechanisms of age-related kidney disease, and specifically to determine the role of the glomerular 
podocyte in causing these pathologies.  In Chapter 1, I will present the major findings in the field 
of chronic kidney disease with regard to factors that are known to be induced or enhanced by aging, 
in order to identify the knowledge gaps that remain and demonstrate areas of needed focus in order 
to identify new therapeutic targets. In Chapter 2, I test the hypothesis that accumulated DNA 
damage can cause accelerated kidney aging using the Ercc1-/∆ mouse model and use this model to 
present new findings about the timing and progression of events that occur with renal aging. 
Finally, in Chapter 3, utilizing cell specific knock-outs of Ercc1, I test the hypothesis that it is the 
glomerular podocyte, not the proximal tubule cell, that causes chronic kidney disease with Ercc1 
deficiency, and I begin to elucidate the mechanism by which this injury occurs.  
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1.1 THE AGING KIDNEY 
1.1.1 Kidney structure and function 
The kidneys filter the entire volume of blood in the body every 30 minutes in order to 
remove excess liquid and wastes. In addition to removing toxins, the kidneys help to control fluid 
and ion levels in the body and also produce calcitriol, the active form of vitamin D, erythropoietin 
to stimulate red blood cell formation in the bone marrow, and renin to control blood pressure(4). 
Understanding how aging affects kidney cell homeostasis will help us to determine who is at risk 
for developing CKD with age and allow us to determine new and effective therapies for age-related 
kidney disease.  
Blood flows into the kidney through the renal artery and then into a million nephrons, the 
functional unit of the kidney. The initial segment of the nephron is comprised of the glomerulus, 
the filtering unit, followed by a proximal tubule, where specific ions, water, and nutrients can be 
reabsorbed from the filtrate into the blood. Fine-tuning of water and ion balance occur downstream 
in the distal nephron and collecting duct, where filtrate eventually flows out of the kidney as urine 
to be stored by the bladder (Figure 2). 
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Figure 2. The kidney nephron 
"Kidney Nephron" by Artwork by Holly Fischer - http://open.umich.edu/education/med/resources/second-
look-series/materials - Urinary Tract Slide 20, 26. Licensed under Creative Commons Attribution 3.0 via 
Wikimedia Commons  
The glomerular filtration barrier consists of the fenestrated, but undiaphragmed, 
endothelial cells that line the tortuous capillary clusters (Figure 3A, red asterisk) of the glomerulus. 
The endothelial cells (Figure 3B, red arrow) adhere to the glomerular basement membrane (GBM) 
(Figure 3B, asterisk). On the other side of the GBM, lies the terminally differentiated, complex 
architecture of the kidney podocyte (aka visceral epithelium). Each podocyte has primary 
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processes that extend from the cell body, which then branch into secondary and tertiary segments, 
called foot processes (Figure 3B, red arrowhead) or pedicels. Foot processes from neighboring 
podocytes interdigitate and are joined together by specialized junctional complexes, called slit 
diaphragms (Figure 3B, blue arrow). The slit diaphragm is a large, signaling protein complex, 
where the protein nephrin from adjacent podocytes homotypically binds on the lateral side of each 
interdigitating foot process, forming a selectively permeable barrier that prevents proteins larger 
than albumin (60kD) from leaving the bloodstream to enter the filtrate. The slit diaphragm is a 
highly complex and regulated signaling center that is tightly coupled to the dynamic podocyte actin 
cytoskeleton. Podocytes are derived from the metanephric mesenchyme and, after the capillary 
loop stage of development, become highly differentiated, post-mitotic cells with high levels of 
basal autophagy(5).  Podocytes are under enormous mechanical and toxic stress and must deal 
with this stress throughout the lifetime of the organism, as there is little or no evidence that they 
can divide or be replaced with age or following injury(6, 7). Genetic diseases in humans and animal 
models have established that podocyte injury is the driving force for glomerulosclerosis(8-10). 
Podocytes are not bound on their apical side; rather filtrate flows through them and into the 
Bowman’s Space (Figure 3A, blue asterisk). This space is lined by Bowman’s capsule, which is 
comprised of the parietal cells (Figure 3A, blue arrow). These cells are thought to be the 
progenitors that can differentiate into either tubule or podocyte cells under certain conditions(11). 
Filtrate from Bowman’s space then passes into the proximal tubule, where protein, water, and other 
substances from the blood can be reabsorbed. Podocyte injury can lead to disruption of the 
glomerular filtration barrier and an increase in the concentration of protein and other substances 
that flow into the filtrate. This can then affect proximal tubule uptake of proteins and eventually 
cause proximal tubule injury and proliferation as an adaptive response(12).  
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Figure 3. The Kidney Filtration Barrier 
(A) TEM image of a healthy adult mouse glomerulus (red arrow indicates entire space with capillary loops). 
Capillary loops (red asterisk) are lined by fenestrated endothelium and podocytes, where materials from the 
blood are filtered into the Bowman’s Space (blue asterisk). The glomerulus is surrounding by parietal 
epithelium (blue arrow), which then differentiate into brush border lined proximal tubule  (red arrowheads). 
(B) TEM image of the glomerular filtration barrier, with fenestrated endothelium (red arrow) lining the 
capillaries, and the interdigitating foot processes of the podocytes (red arrowhead), connected the slit 
diaphragm protein complex (blue arrow). Both the endothelium and the podocytes adhere to and contribute 
to maintaining the GBM (red asterisk). Image taken by Donna Beer Stolz.  
 
Podocytes must dynamically respond to changes in flow and, during health and injury 
states, must dynamically rearrange their actin cytoskeleton to maintain the filtration barrier. 
Therefore, it makes sense that signaling at the slit diaphragm complex affects actin cytoskeleton 
organization(13). This organization changes with injury and has been a target of study, as 
podocytes seem to take on a more migratory phenotype and this may play a role in podocyte loss 
with chronic kidney disease. Podocytes, being post-mitotic, must also manage damaged 
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macromolecules and organelles that accumulate over time, and they depend on a high-rate of basal 
autophagy(5, 14, 15). There is also evidence that podocytes may use autophagy to fuel their protein 
secretion, via content recycling, such as VEGF and glomerular basement membrane components, 
and to regulate the trafficking of slit diaphragm components(16).  
1.1.2 Podocytes and autophagy 
Macroautophagy, herein referred to as “autophagy” (Greek for “self-eating”) is the process 
by which damaged organelles and protein complexes are degraded and resulting materials supply 
nutrients for cell survival(5).  In the first phase of autophagy, nucleation of double-membraned 
structure occurs in an unc-51-like kinase 1 (ULK-1)- and beclin 1-dependent process. Next, 
elongation of the double-membrane occurs in an autophagy related-5 and 12 (ATG5-ATG12) and 
light chain-3 (LC3) conjugation system. During this process, cytoplasmic LC3-I, is converted to 
membrane-bound LC3-II by conjugation with phosphotidylethanolamine. Next, damaged 
organelles and other substrates are enclosed by the double-membraned structure, the 
autophagosome. Unlike the other autophagy proteins mentioned thus far, LC3-II remains 
associated with the autophagasome until contents are degraded and machinery is recycled. 
Therefore, it is commonly used to mark autophagic structures in cells. In addition to labeling LC3-
II, autophagy inhibitors must be used to differentiate between active autophagy and a functional 
block that results in LC3 accumulation(17). Autophagosomes fuse with lysosomes to form 
autolysosomes and the contents are then degraded(18, 19). Finally, contents are released and 
lysosomes are reformed from this structure upon completion of degradation in a mammalian target 
of rapamycin (mTOR)-dependent process(20, 21).  
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In addition to podocytes having the highest rate of autophagy among kidney cells, they also 
display the highest level of mTOR activation(22-25). mTOR is activated at the lysosomal cell 
membrane by various cues such as glucose and amino acids, growth factors, and oxidative stress. 
mTOR, through phosphorylation of various substrates, stimulates a wide variety of anabolic 
processes, such as protein and lipid synthesis, often involved in cellular hypertrophy(22). mTOR 
has been classically known for inhibiting the initiation of macroautophagy through inhibition of 
ULK-1, but it is necessary for lysosomal reformation after autolysosomal degradation, and 
therefore, necessary for autophagic flux(20, 21). Autophagic flux represents the cycling through 
of autophagy in which substrates are degraded, contents of the autolysosome are released, and 
lysosomes have reformed by budding away from the autolysosomal structure.  mTOR also 
regulates slit diaphragm protein expression and podocyte cytoskeletal structure(26). So, how does 
the podocyte achieve both high levels of autophagy and mTOR activation? There is evidence of a 
Tor-Associated Spatial Coupling Compartment (TASCC) in the podocyte that provides a possible 
explanation. LC3-positive autophagosomes are located in a spatially separate compartment from 
mTOR-positive, LC3-positive, autolysosomes (co-localizing with LAMP-2)(16). In this way, 
podocytes achieve initiation of autophagy physically distant from mTOR activation, which occurs 
on the lysosomal membrane. The TASCC is located far from the foot processes in the cell body, 
peri-Golgi, and was also observed in Ras-induced senescent cells, regulating their senescence-
associated secretory phenotype (SASP). Autophagic flux impairment and overall deficiency 
occurs with age(5, 27) and in diseases associated with oxidative stress such as diabetic 
nephropathy, as does an overall increase in mTOR activity(24, 25), Therefore, these two systems 
and their cross talk are likely key players during the process of glomerular aging. Large changes 
in podocyte cytoskeletal arrangement could also affect organization of the TASCC and may have 
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deleterious affects on regulating autophagy and mTOR-dependent processes. Because the TASCC 
was found to control secretion of growth factors and cytokines in cells(16), disruption of this 
structure and its function could contribute to disrupted secretion of GBM components and 
endothelial cell paracrine factors such as VEGF by podocytes. 
1.1.3 Changes in human kidney structure and function with aging 
Kidney function decline, often termed “renal senescence,” is a multi-factorial, complex 
process that is influenced by genetics, gender, diet, activity, chronic inflammation, and other 
comorbid conditions. Kidney disease with aging often displays as glomerulosclerosis, interstitial 
fibrosis, and is defined functionally if an individual has an estimated glomerular filtration rate 
(eGFR) below 60ml/mi/1.73m2, and a urine albumin creatinine ratio (ACR) of greater than or equal 
to 30mg/g (1, 28-33). Epidemiological studies are often performed on populations that have co-
morbidities or confounding factors, such as living donors, making findings difficult to generalize. 
In addition, the method of measuring eGFR is inconsistent and includes serum creatinine 
measurements, inulin clearance, and iothalamate clearance. Serum creatinine levels can change 
with age and CKD-induced muscle deterioration, and often do not accurately reflect the GFR. A 
cross-sectional study in 2011 of 1203 adult living kidney donors, showed that there was a reduction 
in GFR of 6.3ml/min per decade of life(34). Poggio et al, in 2009, in a cross-sectional study of 
1057 prospective kidney donors, found that GFR decreased at an average rate of 1.49 
ml/min/1.72m2 per decade of testing, but that a doubling in the rate of decline of GFR occurred in 
donors over the age of 45(35). The data from these cohorts indicate a progressive loss of renal 
function with aging. However, because a prerequisite of living kidney donation is the absence of 
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CKD and co-morbidities, these results may not accurately reflect the extent of decline in the 
general population.  
The increase in proteinuria and the incidence of glomerulosclerosis, a scarring and 
thickening of glomerular capillaries, point to glomerular aging as a major driver of the loss of 
kidney function seen with age. However, there are also functional changes that indicate the tubules 
change with age. The elderly have increased susceptibility to volume handling, likely due to a 
reduction in sodium excretion in response to dietary salt deprivation(36). Proximal tubule function 
can be measured by lithium clearance and is reduced in elderly patients(37). Additionally, the aged 
are at risk for hyperkalemia, likely due to impaired potassium secretion in the distal nephron and 
collecting duct, which is linked to sodium reabsorption by Na-K-ATPase transporters, which are 
modulated by aldosterone in the tubules(38). Therefore, tubule atrophy or scarring could lead to a 
secondary problem with potassium handling. There is also a decreased capacity of the aged kidney 
to detoxify and metabolize drugs, likely due to a decline in kidney epithelial function(39). 
Similarly, tubule injury could be primary or secondary due to glomerular disease. As of yet, there 
is no clear understanding of the contribution of specific kidney cell types to age-related CKD, and 
the timing of events that occur with aging. It is important to identify this mechanism and target the 
primary cell type(s) involved in propagating aging nephropathy when discovering putative 
therapies.  
Many structural changes have been shown to occur in humans with kidney aging 
(summarized in Table 1), and these are present with varying severity. Overall, the kidney loses 
mass and there is increased calcification and renal cysts(30). An overall decrease in glomerular 
number occurs, and those that remain display hypertrophy, glomerulosclerosis, increased 
mesangial area, thickened GBM(40), and podocyte loss and morphological changes (33, 41). 
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Moving down the nephron, there is tubular atrophy, decreased total tubule length, interstitial 
fibrosis, and increased diverticules(37, 42, 43). There is an overall decrease in vascularity and 
many cases of a-glomerular circulation in nephrons(44). There is an increase in intimal and medial 
hypertrophy, as well as an increase in atherosclerosis. Circulating factors such as Angiotensin II 
increase, and there is a decrease in plasma aldosterone as well as vitamin D activation. All of these 
changes result in an increase in oxidative stress and chronic inflammation(45), a decrease in kidney 
function and repair, and an increased susceptibility to further kidney disease(42).  
1.1.4 Molecular changes that play a role in kidney aging 
The molecular basis of renal aging is under extensive study. Theories of cellular 
senescence, genomic instability, accumulation of oxidative damage(46), and telomeric 
shortening(47) have been explored using both human and animal studies.  On the gene expression 
level, kidneys of elderly individuals differentially express many important genes that could disrupt 
function. There is an over-expression of genes involved in inflammation and extracellular matrix 
synthesis, with a decrease in the expression of genes that regulate lipid and glucose metabolism 
and degradation of extracellular matrix. There is an increase in NF-κB (32, 45, 48) and mTOR 
activation, a decrease in longevity factors such as Klotho(37) and Sirtuin family proteins(42, 49). 
Interestingly, Angiotensin II receptor blockers have been shown to suppress oxidative stress and 
inhibit NF-κB activation and inflammation in aged rat kidneys(50). Many of these molecular 
modulators of kidney aging have been manipulated using genetics and pharmacology in animal 
models of aging, and these studies provide further evidence of their roles in maintaining kidney 
health and extending healthspan and lifespan.  
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Studies in animals have led to a wealth of information as to the changes in kidneys that 
occur with aging. This research takes years and is very costly to perform. Also, there is little 
mechanistic evidence of what drives these age-related changes. Further, different cell types are 
exposed to varying kinds of stress and some can divide or be replaced after damage while others 
cannot. Therefore, the oxidative stress and damage that occurs over time will have different 
outcomes for the various kidney cell types.  What has become clear is that diet, exercise, and 
genetics make the rate of aging and the length of health-span variable for both animals and humans. 
In this section, I aim to present the major modulators of kidney aging uncovered by studying 
animal models of aging to date.  
1.1.4.1 Calorie restriction extends lifespan and uncovers important molecular players for 
renal aging 
Calorie restriction was the first method used to increase lifespan in animal models. In 1935, 
McCay et al established that a reduced calorie diet, without malnutrition, extended maximum and 
average lifespan in rodents(51). Since then, numerous studies in small organisms such as yeast and 
worms, rodents, and primates have been completed in order to identify molecular programs 
involved in extending lifespan during calorie restriction(52-54).  Long-term calorie restriction 
(CR) has been shown to prevent glomerular hypertrophy, mesangial expansion, podocyte loss, and 
glomerulosclerosis(55), markers of senescence(56), and overall evidence of aging 
nephropathy(57). While calorie restriction may not be a viable option for prevention of renal aging 
in humans, it has allowed us to uncover important factors that may serve as therapeutic targets. 
One common thread is that CR changes animal metabolism, and decreases factors that increase 
oxidative damage. Recently it’s been shown that even short-term (8 wks) CR lessens age-
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associated decline in autophagic flux, increased AMPK and SIRT1, decreased age-associated 
mTOR activation and mitochondrial damage, compared to ad libitum fed old rats(56, 58).  
1.1.4.2 Modulation of insulin-like growth factor signaling delays aging in the kidney 
It has become clear that reduction of insulin-like growth factor (IGF-1) signaling is one 
way of extending lifespan and delaying age-related pathologies(59, 60). Interestingly, Klotho 
protein, discussed in the following paragraph, can inhibit IGF-1 signaling, both in vitro and in 
vivo(61). In rats whose Growth Hormone (GH) and subsequent IGF-1 signaling was suppressed 
by an anti-sense GH gene, renal aging was largely prevented. Twenty-four month old transgenic 
mice had significantly fewer sclerotic glomeruli, decreased macrophage infiltration, and decreased 
myofibroblast populations. Suppressing IGF-1 elicits almost identical effects, adding evidence to 
the theory that GH signals mainly through IGF-1(62). When combined with CR, GH suppression 
resulted in an even greater delay of renal aging and extended lifespan significantly(63), suggesting 
there are some additional mechanisms involved in CR-induced preservation of renal function in 
aging. Importantly, mice over-expressing GH, developed evidence of accelerated renal aging with 
diffuse renal glomerulosclerosis(64). Importantly, complete inhibition of IGF-1 or GF can have 
deleterious effects on growth and immune function. Thus there are studies using controlled 
suppression as more viable options for therapies(65).  
1.1.4.3  Klotho maintains kidney health with age 
Klotho is highly expressed in the distal nephron. Klotho protein is secreted by proximal 
and distal convoluted tubules, and mediates its effect by binding to a cell surface receptor and 
repressing insulin/insulin-like growth factor signaling. Klotho mutation in mice leads to a decrease 
in lifespan and accelerated kidney aging(66, 67). Conversely, overexpression of Klotho leads to 
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an extension of lifespan(68). There is evidence that oxidative stress leads to a decrease of Klotho 
in the kidney and this can in turn increase cellular senescence(69). Klotho can also be found as a 
membrane bound form, binding to the transient receptor potential vallinoid-5 (TRPV5) and as a 
cofactor for FGF23 signaling, and has many implications in calcium and vitamin D 
metabolism(70). Klotho mutation leads to accelerated aging disorders such as vascular 
calcifications, ataxia, hypoglycemia, osteoporosis, and hyperphosphatemia, similar to what is seen 
with CKD patients on dialysis. Many more studies are underway to determine the implications of 
Klotho on kidney function and on aging in general(67, 70).  
1.1.4.4 Sirtuin1 modulates NF-kB activity and preserves cellular integrity in the kidney 
Sirtuin1, the most studied member of a family of class III deacetylases, is induced during 
calorie restriction-dependent extension of lifespan(71). SIRT1 is involved in regulation of many 
cellular processes, including metabolism, autophagy, and apoptosis(72). Sirt1 expression is 
decreased in the kidney of aged mice. In addition, heterozygous knockout of the Sirt1 gene causes 
mitochondria in Sirt1-/- mice to resemble those from a mouse two-times older, and CR restriction 
did not prevent this(73). This provides evidence that Sirt1 may be exerting its effects through the 
mitochondria. SIRT1 deacetylates histones and many transcriptional regulators, including NF-κB. 
In the kidney, SIRT1 seems to protect cells from hypoxia, induces autophagy, and lessens fibrosis 
and inflammation(72, 74, 75).  
A common thread between both CR and Sirt1 as longevity factors is the preservation of 
functional autophagy.  Autophagy gene products eventually decline with age. In addition to this, 
autophagy impairment occurs and cells seem to lose their capacity to degrade as seen by the build-
up of autophagic substrates such as p62/Sqstm1, and damaged mitochondria inside of 
autolysosomes.  
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1.1.4.5 Longevity factors in the kidney help to reduce oxidative damage and preserve 
autophagy and degradation 
Could these longevity factors aid in preserving autophagy due to their ability to reduce 
oxidative damage(76)?  Antioxidants, such as resveratrol prevent chronic NF-κB activation seen 
with aging by increasing Sirt1, while also regulating the mTOR activation(77). Perhaps 
preservation of autophagic machinery is also a beneficial side effect of this antioxidant therapy. 
Importantly, studies have shown that antioxidants can prevent Ang II or high glucose-induced 
autophagy in podocytes by decreasing ROS, and thereby decreasing oxidative damage 
accumulation(78, 79). As mentioned above, the post-mitotic podocyte depends on a high-rate of 
basal autophagy to maintain its health. Hartleben et al, provided strong evidence that defective 
autophagy in podocytes causes accelerated kidney aging nephropathy, including accumulation of 
oxidized proteins and damaged organelles(27). In kidney injury states, autophagy is induced to 
reduce damage and restore homeostasis. However, at some point with aging, the degradative 
process fails to work adequately(5, 22, 80, 81), and this leads to proteinuria, glomerulosclerosis, 
and tubule damage(80).  Many suggested therapies involve autophagy-activating drugs, some 
through mTOR inhibition. However, regulated mTOR activation, as discussed above, is important 
for podocyte health and necessary for autophagic flux in podocytes(20, 21). In addition, autophagy 
inducers may fail to work, if the autophagic machinery is no longer functional.  
As we age, there is evidence of accumulation of lipofuscin and free radicals in the 
lysosome, as well as decreased LAMP2 expression(82). This contributes to a decrease in 
autophagy. In addition, mouse studies with inducible LAMP2 expression in the liver, showed 
restored levels of autophagy, restored healthy mitochondria, and clearance of damaged 
biomolecules that accumulate with aging(83). Additionally, compounds that activate TFEB, a 
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transcription factor that induces lysosomal and autophagy genes, restore autophagy and lysosomal 
reformation in LPS-induced septic hearts, ameliorating damage(84). Perhaps, since it is not always 
plausible to prevent age-related pathologies in the kidney, therapies that aim to restore autophagy-
lysosomal function may be a more effective method to reverse aging pathologies.  
1.1.5 Questions that remain 
Research in animals has taught us a lot about the factors and genetic programs involved in 
renal aging, but these studies are lengthy and have yet to provide us with clear evidence of the 
mechanism of progression and the role of various cell types in propagating age-related CKD. The 
information provided here on changes that occur with kidney aging is summarized in Table 1. 
While it seems as though glomerular damage may be a key component, it is not clear as to whether 
this damage is causing subsequent tubule injury and CKD with aging. Perhaps damage 
accumulation in the tubules is playing a large role in causing functional decline. There is a need 
for better models that allow for timely studies of the progression of aging nephropathy, as well as 
tools with which we can separate out the roles of the various cells in the nephron. But, how is it 
possible to cause aging in one cell type while maintaining the inherent health of the others? This 
thesis utilizes a mouse model of human progeria and the power of genetic manipulation to begin 
to answer these questions.  
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 Table 1. Summary of Kidney Changes with Aging. 
Structural Changes Functional Changes Altered Genes/Factors  
Decreased kidney mass, thinning 
cortex(31) 
Decreased GFR(42) Decreased Klotho(85) 
Glomerulosclerosis(32) Increased urinary ACR(5) Increased NF-κB activation(32) 
Thickened GBM(86), TBM(40) Hyperkalemia(38) Increased mTOR activation(87) 
Interstitial Fibrosis(88) Reduced sodium conservation(36) Decreased autophagy genes, 
impaired autophagic 
degradation(27) 
Tubule Atrophy, loss(89) Decreased concentration of 
urine(90) 
Decreased Sirt1(72) 
Membranous nephropathy(28) Impaired fluid balance(91) Increased p16, p21, p53 protein 
Increased calcification(70), cysts Decreased capacity to decrease 
urinary pH(42) 
Decreased antioxidant genes, e.g., 
ceroplasmin(92) 
Decreased vascularity(93) Decreased vitamin D activation(94) Increased Ang II signaling(95)  
Increased intimal/medial 
hypertrophy(42) 
 Decreased aldosterone in 
circulation(96) 
Glomerular hypertrophy(55), 
decreased glomerular #(97) 
 Decreased plasma RA(96) 
Podocyte effacement, loss(98)  Increased fibrotic factors(99) 
Mesangial proliferation(28)   
Increased macrophage 
infiltration(62) 
  
damaged mitochondria(56), 
accumulating  autolysosomes(81) 
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Table of structure and functional changes in the aging kidney, as well as genes and other factors that are altered in 
aged kidneys and have been shown to play a role in kidney aging. Abbreviations used: Glomerular Basement 
Membrane (GBM), Tubular Basement Membrane (TBM), Glomerular Filtration Rate (GFR), Albumin Creatinine 
Ratio (ACR), Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-κB), mammalian Target of 
Rapamycin (mTOR), NAD dependent deacetylase sirtuin-1 (Sirt1), Angiotensin II (Ang II), Renin-angiotensin (RA) 
 
 
1.2 ERCC1 MODEL OF ACCELERATED AGING 
Aging is a complex process that manifests differently in each cell type, and depends on the various 
levels of stress, replication, environmental factors, and genetic regulatory programs that are present 
in each tissue and cell.  Endogenous DNA damage occurs in all cell types to various extents, and 
as our cells age, any damage not repaired may accumulate and promote the aging process. The 
ERCC1 (Excision Repair Cross Complementary Group 1) protein forms an endonuclease that, 
along with its obligate binding partner, XPF (Xeroderma Pigmentosum Group F), is involved in 
various kinds of DNA damage repair. It is most well known for its function in nucleotide excision 
repair (NER) of bulky chemical lesions, but is also important in the repair of some double-strand 
breaks (DSBs) and interstrand crosslinks (ICLs)(100, 101).  Human disease is caused by deficiency 
of XPF or Ercc1, including xeroderma pigmentosum (XP)(102), an accelerated aging or progeroid 
disease called XFP progeroid syndrome, cerebro-oculo facioskeletal syndrome (COFS)(101), 
Cockayne Syndrome (CS), and Fanconi Anemia(103-105). These rare but serious diseases have 
led to the development of mouse models, and have illustrated that Ercc1 and XPF are important in 
preventing age-related pathologies.  
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1.2.1 ERCC1-XPF DNA repair enzyme in human health and disease 
The XPF-ERCC1 binding pair is an endonuclease responsible for excision at the 5’ end of 
various types of DNA lesions(106). The XPF protein contains the endonuclease catalytic activity 
and ERCC1, its binding partner, is necessary for binding to DNA. The pair excises UV damaged 
nucleotides, such as cyclopyrimidine dimers (CPDs) during nucleotide excision repair. Therefore, 
humans with ERCC1 or XPF deficiency (XP) have extreme photosensitivity and an extremely high 
incidence of cutaneous and ocular neoplasms(107). However, the Ercc1-XPF pair are also 
involved in repairing ICL’s and DSB’s, so deficiency of either protein has diverse effects in 
multiple tissues as cells divide and are exposed to different levels of oxidative damage.   
Patients with XPF or Ercc1 mutations have a range of photosensitivity and onset of skin 
carcinomas, as well as severe neurodegenerative and ocular defects, and some patients have 
accelerated aging or progeroid syndrome(101), including neurodegeneration, renal insufficiency, 
loss of subcutaneous fat, liver disease, kyphosis, vision and hearing loss, appearing in 
prepubescence.  Patients with various mutations display a variety of symptoms. One patient with 
an Ercc1 mutation had severe COFS syndrome(108), and another had severe neurodegeneration 
that was progressive and resulted in cortical atrophy and dementia. Another patient had 
pronounced progeroid features, severe renal insufficiency (GFR: 17ml/min x 1.73 m2 and 
proteinuria with levels of 1.8g/m2/24hr) and extremely small and dense kidneys. As a result, he 
had hypoalbuminemia, anemia, and acidosis, as well as elevated liver enzymes, optic atrophy, 
ataxia, and many other aging pathologies. These symptoms are not usually seen in XP patients, 
who primarily have symptoms of UV-sensitivity and sometimes neurodegeneration. However, this 
patient cell’s also displayed only 5% of the normal UV-induced DNA repair, consistent with 
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XP(102) and he had an Xpf mutation. This discovery led to a new progeroid syndrome called XFE, 
and another patient with strikingly similar symptoms was recently been identified(101).  
The clinical manifestations and severity of disease likely depend on how each mutation 
affects the protein expression and subcellular localization of the XPF-ERCC1 complex.  These 
accelerated aging symptoms are strikingly similar to what is seen in mouse models deficient in 
either Ercc1 or XPF. Knock-out mice for Xpf or Ercc1 have identical phenotypes of accelerated 
aging(101), supporting the evidence that XPF and ERCC1 are obligate partners and rely on each 
other for stability and function.  
1.2.2 Ercc1 deficient mouse models.  
The Ercc1 gene was first knocked out by McWhir et al(109) and by another independent 
laboratory, Weeda et al(110). Knock-out is lethal in true inbred mice, and therefore is studied in a 
mixed background of C57BL/6 and FVB/n.  Ercc1-/- mice live approximately 28 days and display 
severe neurodegeneration and very accelerated aging phenotypes. Genome-wide mRNA 
expression levels were compared between Ercc1-/- mice and their wild-type (WT) littermates, to 
those that occur between young and old WT, and significant overlap was observed, providing some 
evidence that endogenous DNA damage may contribute to aging pathologies.  XPF knockouts, 
first created by Tian et al., (111), have a strikingly similar phenotype to Ercc1-/- mice, displaying 
the same neurodegenerative and liver function defects. The Ercc1 deficiency in a mouse was 
corrected in the liver only of knock-out mice improved many symptoms including growth and 
lifespan(112). However, these animals developed renal insufficiency by 7 weeks and progressive 
chronic kidney disease, suggesting that the kidney and liver cells in Ercc1 -/- mice are some of the 
most sensitive to endogenous DNA damage.  
 20 
In order to mirror some of the human diseases and study the progression in a longer lived 
Ercc1 deficient mouse, a truncated Ercc1 allele was created that results in reduced Ercc1 message 
levels and only about 10% of the protein expression levels(110). When this allele is combined with 
a null allele, resulting in the Ercc1-/∆  mouse, the phenotype is very similar in all organ systems to the Ercc1-/- mouse. However, they are born with Mendelian frequency, display progressive aging pathologies after development, and live 6-7 months (Figure 4)(101). Therefore Ercc1-
/∆  mice serve as a slower, more physiologically relevant, accelerated aging model(101). This model is then useful in studying the mechanism of aging in various tissues, as well as identifying new targets for therapy.  
Figure 4. Lifespan of Ercc1 Mouse Models 
The liver of the Ercc1-/∆  mouse exhibited characteristics of accelerated aging by 20-23 weeks of age(113). These included sinusoidal changes, such as thickening of endothelial cells, deposition of basement membrane and defenestration, inflammation, loss of liver regenerative capacity, and loss of function as indicated by serum markers.  In addition, and similar to naturally aged WT livers, the Ercc1-/∆  livers showed cell  senescence, shown by 
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p16 expression, SA-β−galactosidase (SA-β−gal) activity and large nuclear size. Finally, there was 
evidence of oxidative damage, shown by increased lipid peroxidation and accumulation of 
lipofuscin and oxidative DNA damage(114), all characteristic of natural aging(82, 113, 115-117). 
This demonstrates that the Ercc1-/∆  mouse is a useful tool to study liver aging.  In this thesis, I will demonstrate that it is also a valuable and accurate tool to study the progression of kidney aging, which seems to occur at a younger age in the Ercc1-/∆  than the detected liver age-related changes.  
 
1.3 SUMMARY 
Kidney aging likely plays a large role in the high incidence of CKD and ESRD that occurs in the 
U.S. and worldwide(28, 118). There is a wealth of descriptive information about the functional 
and structural changes that occur in kidney aging, but it is nearly impossible to decipher the 
progression and mechanism in humans who typically have multiple confounding factors. 
Therefore, we rely largely upon animal models. Rodent models have been useful because of similar 
changes observed with human kidney aging, and they allow for genetic manipulation. These 
studies have identified many factors involved in the aging process, as well as longevity factors that 
protect renal function from deleterious aging pathologies. In mice and rats, these studies take years 
and largely involve comparing old animals to young. It is very time-consuming and costly to try 
to learn about the timing and progression of events that occur over the course of 2-3 years. 
Additionally, it is difficult to separate out the roles of various kidney cells in driving aging 
nephropathy. The Ercc1 deficient mouse models of human progeria provide an efficient and 
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accurate way of studying the aging process due to endogenous DNA damage. Secondly, they 
provide a way to determine cellular roles in driving aging diseases using cell specific knock out of 
the Ercc1 gene. In this way, the mouse models presented in this thesis may facilitate discovery of 
targeted therapies.  Finally, this accelerated aging model will also be useful in discovery of new 
aging biomarkers. It has become apparent that kidney aging does not occur at the same rate or to 
the same extent in all individuals, and this may impact what therapies are appropriate in CKD 
patients. In the following chapter, I will present the Ercc1-/∆ mouse model of accelerated kidney 
aging, validating it by comparing it systematically to naturally aged mice. Finally, in Chapter 3, I 
will determine the timing and progression of pathological changes with aging, and I will use cell-
specific knock-outs to show that the glomerular podocyte is the main renal cell responsible for 
driving age-related CKD in the Ercc1 deficient mouse.  
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2.0  ACCELERATED RENAL AGING IN THE ERCC1 DEFICIENT MOUSE 
MODEL OF HUMAN PROGERIA 
Chapter 2 is adapted from:  Kathryn E. Wack, M.S., Siobhán Q. Gregg, Ph.D., Tania A. 
Rozgaja, Ph.D., Amanda P. Beck, D.V.M., D.A.C.V.P., Sheldon Bastacky, M.D.,  Verónica 
Gutiérrez, M.Sc., Andria R. Robinson, Ph.D., Mark A. Ross, B.Sc., Lora H. Rigatti, 
D.V.M., Jing Zhao, B.S., Tyler Woodell, M.D., Jin Wang, Ph.D. Mohammad Fallahi-
Sichani, M.S., Paul D. Robbins Ph.D., Yinsheng Wang, Ph.D., Donna Beer Stolz, Ph.D., 
Laura J. Niedernhofer, M.D., Ph.D. (2014) Accelerated renal aging in a murine model of 
progeria caused by a DNA repair defect.  Paper is currently in submission.  
 
With aging, kidney structure and function are lost leading to increased risk of chronic kidney 
disease (CKD), end-stage renal disease and mortality. The incidence of CKD is rising, thus animal 
models of rapid renal aging are needed to accelerate research on causes and treatments of CKD. 
Ercc1-/Δ mice model a progeria caused by low expression of the DNA repair nuclease ERCC1-
XPF. Ercc1-/Δ mice develop progressive multi-organ degeneration over a 7 month lifespan. To 
determine if Ercc1-/Δ mice mimic natural renal aging, structural and functional changes in the 
kidneys from progeroid mice were compared to those of old wild-type (WT) mice. Renal 
development was normal in Ercc1-/Δ mice but by 6 mo of age the animals exhibited 
glomerulosclerosis and tubulointerstitial fibrosis similar to 2-3 yr-old WT mice. Ercc1-/Δ mice 
developed albuminuria and podocyte effacement by 1 mo. At 2 mo, the glomerular filtration rate 
was reduced 5-fold in Ercc1-/Δ mice similar to 2 yr-old WT mice. At 5 mo, the blood urea nitrogen 
in Ercc1-/Δ mice was doubled and the extent of podocyte degeneration matched 2 yr-old WT mice. 
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Both progeroid and old WT mice had increased intracellular adhesion molecule-1 and smooth 
muscle actin-positive cells, macrophage infiltration, senescence markers and endogenous 
oxidative DNA damage. These data demonstrate that renal aging is accelerated 5-6 fold in Ercc1-
/Δ mice and endogenous DNA damage plays a causative role in CKD. 
 
2.1 INTRODUCTION 
Chronic kidney disease (CKD) is a major health concern because its incidence is increasing, patient 
outcome is poor, and the costs associated with treatment are high (119). Aging is a major risk 
factor for CKD and other age-related conditions such as diabetes and hypertension compound this 
risk. CKD can lead to end-stage renal disease (ESRD) and it is also predictive of cardiovascular 
disease (120). Renal diseases are the ninth leading cause of death in the USA (121). Approximately 
70 billion dollars is spent worldwide on medical costs associated with ESRD (122). Animal models 
of rapid kidney aging would dramatically accelerate research on the molecular basis of renal aging 
and susceptibility to CKD, as well as treatments. 
Increased age is associated with a reduction in renal cortical mass(41). Renal senescence 
encompasses the age-related changes that occur in the kidney with aging and includes interstitial 
fibrosis, tubular degeneration and glomerulosclerosis and a linear decline in glomerular filtration 
rate (GFR) after the fifth decade of life (123). There is also up-regulation of ICAM in endothelium 
and macrophage infiltration with aging (45), indicative of inflammation. Shortened telomeres and 
increased expression of the senescence marker p16INK4a are observed in kidneys from elderly 
patients (47, 124).  
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The environmental and genetic variability in humans makes studying renal aging challenging. 
Mice are a useful model system because these variables can be controlled. However, it still requires 
a lengthy investment to perform studies on aged (2-3 yr old) mice. One approach to overcome this 
is to use mouse models of accelerated aging or progeria. Werner, Cockayne and XFE progeroid 
syndromes are examples of inherited diseases with accelerated aging of one or more tissues (125).  
Patients with XFE progeroid syndrome display accelerated aging of all organ systems 
beginning in the second decade of life, including renal insufficiency and proteinuria (102). XFE is 
caused by mutations in XPF, which encodes one subunit of the DNA repair endonuclease Excision 
repair cross complementation group 1-Xeroderma pigmentosum group F (ERCC1-XPF). The 
enzyme is involved in the repair of DNA lesions including interstrand crosslinks, double-strand 
breaks and helix-distorting monoadducts (100, 106, 126). ERCC1 and XPF are obligate binding 
partners, stabilizing one another in vivo (127). Accordingly, Ercc1-/- and Xpf-/- mice have an 
identical phenotype (110, 111). Ercc1-/- mice die in the 4th wk of life with age-associated 
degenerative changes, including osteoporosis, neurodegeneration, bone marrow hypoplasia, 
epidermal atrophy, sarcopenia and liver and kidney dysfunction (102, 112, 128). We and others 
previously described Ercc1-/Δ mice, a hypomorphic model of XFE progeroid syndrome that 
express approximately 5% of the normal complement of ERCC1-XPF and live longer than Ercc1-
/- mice (28 vs. 4 wks) (113, 129-131). Ercc1-/Δ mice are healthy into adulthood (8 wks) then begin 
to show progressive symptoms associated with aging. The aim of this study was to systematically 
compare the kidney of progeroid Ercc1-/Δ mice to that of old wild-type (WT) mice (2+ yrs-old) to 
determine if the renal degeneration occurring in Ercc1-/Δ mice is an accurate model of natural aging 
that could be used to accelerate research on the biology of kidney aging and therapeutic 
interventions to prevent, delay or ameliorate CKD in old age. 
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 2.2 MATERIALS AND METHODS 
Animal Care and Experimentation 
Animal work was approved by the University of Pittsburgh and Scripps Florida Institutional 
Animal Care and Use Committees and is in accordance with NIH guidelines for humane care of 
animals. Ercc1-/Δ mice were bred and genotyped as previously described (126). All mice were in a 
congenic f1 background generated by crossing inbred FVB/n and C57Bl/6 mice. 
Histological analyses 
Ercc1-/Δ mice at 8 wks (pre-symptomatic adults), 16 wks (progeroid) and 23 wks (near terminal) 
were sacrificed by CO2 inhalation with age-matched and old (25 and 36 mo) WT mice. Some 
animals were injected intraperitoneally with bromodeoxyuridine (BrdU; 50μL of a 10 mg/ml 
solution in sterile Dulbecco’s phosphate-buffered saline (PBS); BD Pharmingen, San Jose, CA) 
weekly x 8 wks to label proliferating cells. Post-mortem, the kidneys were excised and fixed with 
10% formalin and embedded in paraffin. Tissue sections (6 µm) were cut and stained with 
haematoxylin and eosin (H&E), Masson trichrome, and Periodic acid-Schiff stain (PAS). 
Alternatively, tissue specimens were cryopreserved by fixation in 2% paraformaldehyde in PBS 
for 2-4 hours, followed by 30% sucrose at 4°C overnight, then frozen in liquid N2-cooled 
isopentane for sectioning on a Microm™ HM 525 cryostat (Thermo Scientific; Waltham, MA).  
Quantification of cPu lesions as a measure of oxidative DNA damage 
5’R and 5’S diastereomers of 8,5’-cyclopurine-2’deoxynucelosides in genomic DNA isolated from 
whole kidney lysates were measured by LC-MS/MS/MS as previously described (114).  
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Kidney perfusion and processing for ultrastructural analysis 
For EM, the kidney of euthanized animals was cleared of blood by perfusion with PBS at 3 mL/min 
via cardiac puncture then perfuse-fixed with 2.5% glutaraldehyde and processed as described 
previously (113). 350 nm sections were cut and stained with Toluidine Blue. TEM images were 
captured with the JEOL JEM 1011 microscope and SEM images were taken with the JEOL JSM 
6330F microscope (JEOL Ltd, Peabody, MA).  
Immunohistochemical analyses 
IHC was performed on deparaffinized kidney sections as previously described (113). Endogenous 
peroxidase activity was blocked with 3% H2O2. Sections were subjected to heat induced-epitope 
retrieval in sodium citrate buffer (10 mM, pH 6.0) for 30 min in a decloaker, followed by 30 min 
cool-down. Blocking was done with 5% rabbit serum for 20 min. Detailed information about 
antibodies is provided in supplemental information. Hematoxylin was used as a counterstain. 
Primary antibody (sheep anti-BrdU, Abcam, Cambridge, MA) was applied for 1 hr at room 
temperature (1:200). Biotinylated secondary antibody was applied for 30 min (1:1000) followed 
by VECTASTAIN avidin:peroxidase detection complex (ABC Elite, Vector Laboratories, 
Burlingame, CA) for 30 min. 3,3C Elite, Vector La (DAB) chromagen (Dako Cytomation, 
Carpinteria, CA) was applied for 6 min, followed by a two rinses with distilled water. Hematoxylin 
was used as a counterstain. Bright field images were captured using an Olympus BX51 fluorescent 
microscope.  
Immunofluorescence analyses  
IF was performed on frozen kidney sections as previously described (113). Briefly, kidneys were 
fixed in 2% paraformaldehyde in PBS for 2-4 hrs followed by 30% sucrose at 4°C overnight, then 
frozen in liquid N2-cooled isopentane and sectioned (7 µm thick) on a Microm™ HM 525 cryostat 
 28 
(Thermo Scientific; Waltham, MA). Primary antibody was incubated at room temperature for 1 hr 
(goat anti-CD68, Santa Cruz Biotechnology, Inc., Santa Cruz, CA; anti-SMA:Cy3, Sigma, St. 
Louis, MO; rat anti-CD45 or rat anti-CD31 (PECAM) both from BD Pharmingen, San Jose, CA; 
or hamster anti-ICAM, BD Biosciences, San Jose, CA) all at a dilution of 1:100. Sheep anti-BrdU 
(Abcam, Cambridge, MA) was 1:200. Anti-phospho-γH2AX (Ser139) (Millipore, Billerica, MA) 
was incubated overnight at 4°C at 1:200. The secondary antibodies (Invitrogen, Eugene, OR; 
Jackson ImmunoResearch Laboratories, West Grove, PA), were added for 1 hr in the dark at room 
temperature. Rhodamine-labeled wheat germ agglutinin was used at 2 µg/ml and incubated for 30 
min at room temperature (Rhodamine Lectin Kit I, Vector Laboratories, Burlingame, CA). Nuclei 
were stained with Vectashield with DAPI mounting medium (Vector Laboratories, Inc., 
Burlingame, CA). Images were acquired using an Olympus Fluoview 1000 inverted confocal 
microscope. 
Albumin/creatinine ratio measurement 
Urine was collected first thing in the morning weekly and albumin levels measured using an 
Albumin Elisa Kit (Bethyl Laboratories, Montgomery, TX) normalized to creatinine levels using 
the Creatinine Urine Assay Kit (Cayman Chemical, Ann Arbor, MI). An n=3 was used for each 
time point and the average values plotted ± S.E.M.; significance was calculated using the Student’s 
two tailed t-test; *p < 0.05.  
Determination of GFR 
GFR was measured using FITC-inulin clearance by modified protocol (132). Briefly, mice (n=3 
per group) were given a bolus injection of a 2.5% FITC-inulin (Sigma-Aldrich, St. Louis, MO) 
solution retro-orbitally (2 µl per g body weight). Blood was collected from the tail tip before 
injection and 3, 5, 7, 10, 15, 20 and 40 min post-injection. Plasma was isolated and samples were 
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diluted 1:10 in 0.5M Hepes. FITC fluorescence was measured in duplicate for each animal using 
a Perkin Elmer EnVision 2104 Multilabel Reader. GraphPad Prism was used to plot FITC-inulin 
concentration using a two-phase exponential decay model. GFR was normalized using body 
weight and expressed as µl/min/g BW.  
Renal function  
Blood was collected by heart puncture from 6 animals per group and placed in plasma separator 
tubes coated with lithium heparin (BD Microtainer, Franklin Lakes, NJ). The plasma was sent to 
Antech Diagnostics (Pittsburgh, PA) for renal function tests. The average of values from 6-7 mice 
were plotted ± S.D. significance was calculated using the Student’s two tailed t-test; *p<0.05.  
Immunoblotting 
Flash frozen renal tissue was weighed and homogenized in RIPA buffer (Thermo Scientific, 
Pittsburgh, PA) containing Complete mini-protease inhibitor cocktail (Roche, Branchburg, NJ). 
25 g protein was resolved on 4-20% Mini Protean TGX polyacrylamide gels (Bio-Rad) and 
proteins detected as previously described (113). p53 was detected with mouse anti-p53 (1:900, 
Cell Signaling, Beverly, MA). p21 was detected with rabbit anti-p21 (1:450, Abcam, Cambridge, 
MA). p16 was detected with mouse anti-p16 (1:100, Santa Cruz, Santa Cruz, CA). γ−H2AX was 
detected with mouse anti- γ-H2AX (1:1000, Millipore, Billirica, MA). Tubulin was used as a 
loading control and detected with rabbit anti-tubulin (1:7500, Abcam, Cambridge, MA). 
Secondary antibodies used were either anti-rabbit HRP (1:3000, Invitrogen, Carlsbad, CA) or anti-
mouse HRP (1:3000, Cell Signaling, Beverly, MA). 
Analysis of Gene Expression Data 
 The kidney Affymetrix dataset GSE43061 was downloaded from NCBI GEO database. The 
Mouse Gene 1.0 ST chip CEL files were imported into GeneSpring GX v12.1. The Robust Multi-
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array Average (RMA) algorithm was utilized to calculate probe-set signals on each chip. The 
summarization algorithm was set to ExonRMA16 and the normalization parameter was set to 
quantile. Probe sets with signal higher than chip 20th percentile were selected for statistical 
analysis, which allowed one wildcard in each group of replicates. The Ercc1-/  14 wk and W   
wk were compared to the WT 14 wk. To find differentially expressed probe sets in each 
comparison GeneSpring filter on the Volcano plot function was used. The unpaired t-test p-value 
cut-off was set to 0.05, the fold change cut-off was set to 1.5, and the p-value computation method 
was set to Asymptotic. Two lists of differentially expressed probe sets were created based on the 
above comparisons. The shared probe sets between these two lists were identified and annotated 
in GeneSpring. R programming language was used to calculate the overlap p-value between the 
two differentially expressed gene lists. 
TUNEL Assay 
To detect apoptotic cells, kidneys were fixed in 2% paraformaldehyde in PBS for 2-4 hrs followed 
by 30% sucrose at 4°C overnight then frozen in liquid N2-cooled isopentane and sectioned on a 
Microm™ HM 525 cryostat (Thermo Scientific; Waltham, MA). The kidney  sections were stained 
with the terminal deoxynucleotidyl  dUTP nick ending labeling (TUNEL) kit (Roche, Indianapolis, 
IN), followed by an anti-streptavadin-Cy5 secondary antibody (Jackson Immunoresearch, West 
Grove, PA). Samples were co-stained with DAPI nuclear stain and mounted with gelvatol under 
coverslips. Samples were then imaged on an Olympus Fluoview 1000 confocal microscope at 
200X and analyzed for co-localization of TUNEL stain and DAPI. The kidney from a 18 wk-old 
normal mouse isolated 1 month following exposure to 0.175 Gy of total body ionizing radiation 
weekly x 4 weeks was used as a positive control.  
Detection of Senescence-Associated β-Galactosidase 
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Tissues fixed in 10% formalin for 4 hrs at 4°C were embedded in O.C.T. compound (Tissue-Tek, 
Sakura, Torrance, CA) then cryosectioned at 5 mM thickness using a Leica Cryostat. Slides were 
storedat -80°C until staining. Tissue sections were thawed by washing them in PBS and then 
stained for SA-bgal activity using X-gal staining solution (40 mM citric acid in sodium phosphate 
buffer, 5 mM K4[Fe(CN)6] 3H2O, 5 mM K3[Fe(CN)6], 150 mM sodium chloride, 2 mM 
magnesium chloride and 1 mg/ml X-gal dissolved in N,N-dimethylformamide) at pH 6 for 5-6 
hours at 37°C as described previously (133). Slides were mounted with VectaShield (Vector 
Laboratories, Burlingham, CA) and visualized under bright field microscopy using an Olympus 
microscope at 10X magnification.  
 
2.3 RESULTS 
2.3.1 Histopathologic changes in progeroid Ercc1-/Δ mouse kidney mimic normal aging 
To investigate structural changes in the kidney of progeroid Ercc1-/Δ mice, we compared renal 
tissue of 8, 16, and 23 wk-old Ercc1-/Δ mice to age-matched and old (25 and 36 mo) WT mice 
(Figure 5A). Histologic evaluation of hematoxylin and eosin (H&E) stained sections revealed 
normal kidney architecture in 8 wk-old Ercc1-/Δ mice demonstrating that their renal development 
is normal. In contrast, the kidneys from 16 and 23 wk-old Ercc1-/Δ exhibited glomerular changes, 
including increased mesangial matrix and segmental thickening of capillary loops. Similar lesions 
were observed in much older WT mice (25 and 36 mo-old). Additionally, the 36 mo WT mice had 
multiple foci of tubulointerstitial mineralization, not observed in younger WT animals. None of 
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the above lesions were observed in 8 wk Ercc1-/Δ or 16 and 25 wk WT mice, demonstrating that 
the lesions are degenerative in nature. Period acid-Schiff’s (PAS) reagent staining revealed 
thickening of glomerular capillary loops in the 16 and 23 wk-old Ercc1-/Δ and 25-36 mo-old WT 
mice, in addition to thickened glomerular and tubular basement membranes in the 23 wk-old 
Ercc1-/Δ and 25-36 mo-old WT mice. Masson’s trichrome staining indicated mild tubulointerstitial 
fibrosis in the 16 wk Ercc1-/Δ mice and varying degrees of tubulointerstitial fibrosis and 
glomerulosclerosis in the 23 wk Ercc1-/Δ and 25-36 mo-old WT mice. Sections from progeroid and 
aged kidney with glomerulosclerosis were stayed with Congo Red to detect glomerular amyloid 
deposition and all samples were negative. Interstitial fibrosis and glomerulosclerosis are common 
in kidneys of aged humans (30). These data suggest that normal aging-related degenerative 
changes occur spontaneously and rapidly in kidneys of Ercc1-/Δ mice.  
The degenerative changes that occur in Ercc1-/Δ mice are presumed to arise as a consequence 
of failure to repair endogenous DNA damage (134). 8,5’cyclopurine-2’deoxynucleosides are 
oxidative lesions that occur endogenously (135). We previously demonstrated that the four 
diastereomers of cyclopurine lesions (5’R and 5’S of dA and dG cPu) accumulate with aging in 
WT and more rapidly Ercc1-/Δ mice, but in a tissue specific manner (114). At 10 wks of age, when 
Ercc1-/Δ mice do not have extensive histopathologic changes in the kidney, the level of cPu lesions 
in the kidneys of these mice is similar to that of WT littermates (Fig. 5B). By 21 wks of age, the 
level of cPu lesions increased 4-fold in the kidney of Ercc1-/Δ mice. This was significantly higher 
than cPu levels in age-matched WT mice, but similar to 3 yr-old WT mice. Thus, identical 
oxidative DNA lesions accumulate with accelerated and normal aging, and there is a strong 
correlation between elevated levels of DNA damage and onset of CKD. 
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Figure 5. Histopathological changes in progeroid Ercc1-/Δ and aged WT mouse kidneys 
(A) Histologic evaluation of kidneys from Ercc1-/Δ mice of increasing age as well as age-matched controls and old 
WT mice. Hematoxylin and eosin (H&E) stained sections from 16 and 23 wk Ercc1-/Δ and 25 and 36 mo WT mice  
glomerular lesions, including increased mesangial matrix and segmental thickening of capillary loops (arrows). In 
addition, 23 wk Ercc1-/Δ, 25 and 36 mo WT mice display thickening of the glomerular basement membrane. The 36 
mo WT mouse has multiple foci of tubulointerstitial mineralization (arrowhead). Period acid-Schiff’s (PAS) reagent 
staining highlights the thickening of glomerular capillary loops (arrows) in the 16 wk and 23 wk  Ercc1-/Δ and 25 and 
36 mo WT mice, in addition to thickened glomerular and tubular basement membranes (arrowhead) in the 23 wk  
Ercc1-/Δ and 25 and 36 mo WT mice. Masson’s trichrome staining revealed mild tubulointerstitial fibrosis (star) and 
glomerulosclerosis (arrow) in the 16 and 23 wk Ercc1-/Δ as well as the 25 and 36 mo WT mice. In all panels, scale bar 
= 50µm. (B) Accumulation of oxidative DNA damage in kidney with normal and accelerated aging. Data from Wang 
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et al (114) were re-graphed to indicate the total number of cyclopurine lesions (5’R-cdA + 5’S-cdA + 5’R-cdG + 5’S-
cdG) per 106 nucleosides. The values represent the mean and standard error from kidney of 3 animals per group. An 
unpaired two-tailed t-test was used to calculate p values. *p,0.05; **p<0.01;***p<0.001. 
 
2.3.2 Functional changes in progeroid Ercc1-/Δ mouse kidney mimic normal aging 
Renal function can be assessed by examining clinical chemistries. High levels of urea, a 
nitrogenous waste product, in the serum can indicate decreased renal function (136). Blood urea 
nitrogen (BUN) levels were normal in 7-12 wk-old Ercc1-/Δ mice, but by 20 weeks of age, the 
mutant mice exhibited significantly elevated BUN values compared to their normal siblings (Table 
2). In mice, alkaline phosphatase (ALP) is found in the highest concentration in the kidney and 
intestine (137). Elevations in ALP may reflect acute renal damage due to increased cell death or 
reduced serum clearance of the enzyme (138). By 6-7 wks of age, Ercc1-/Δ mice had significantly 
increased ALP values compared to age-matched controls indicating parenchymal injury. Serum 
lipase was also significantly elevated by 6-7 wks of age in Ercc1-/Δ mice compared to age-matched 
controls. Though serum lipase is not renal-specific, it is excreted by the kidney  
and may be elevated with renal disease due to decreased clearance (138). 
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Genotype Age 
(wks) 
BUN 
(mg/dL) 
ALP (U/L) Lipase (U/L) Albumin 
(g/dL) 
Creatinine 
(mg/dL) 
WT 6-7 24 ± 5 146 ± 26 86 ± 25 3.1 ± 0.5 0.37 ± 0.12 
 10-12 25 ± 6 112 ± 15 91 ± 15 3.4 ± 0.3 0.36 ± 0.05 
 20-23 23 ± 4 56 ± 13 67 ± 3 2.9 ± 0.2 0.32 ± 0.04 
 108-128 26 ± 16 48 ± 21 75 ± 32 2.8 ± 0.4 0.32 ± 0.04 
Ercc1-/∆ 6-7 25 ± 6 208 ± 40* 120 ± 18* 2.7 ± 0.2 0.37 ± 0.16 
 10-12 29 ± 8 207 ± 81* 132 ± 20* 2.5 ± 0.6* 0.32 ± 0.04 
 20-23 60 ± 26*,** 316 ± 170* 132 ± 31* 1.9 ± 0.5*,** 0.42  ± 0.15 
Table 2. Serum chemistries relevant to renal function 
*p<0.05 between Ercc1-/∆ and age matched controls (Student’s two tailed t-test). 
**p<0.05 between age groups of one genotype (Student’s two tailed t-test). 
 
Hypoalbuminemia may develop secondary to the loss of protein via the glomerular membrane 
and/or failure of tubular reabsorption (138-140). At 10-12 wks of age, Ercc1-/Δ mice had 
significantly lower serum albumin levels than age-matched controls. By 21 weeks of age, Ercc1-
/Δ mice exhibited hypoalbuminemia. Serum creatinine levels did not differ significantly from 
controls at any age.  
Glomerular filtration is a direct measure of renal function. GFR was measured by determining 
the rate of FITC-inulin clearance from the blood (Figure 6A). Adult WT mice had a GFR within 
normal range (141) (8-12 µl/min/g body weight. The GFR was within normal range for 4 wk Ercc1-
/Δ mice (9.2 µl/min/g). But by 8 wks of age, the Ercc1-/Δ mice had a significantly reduced GFR of 
2.4 µl/min/g. Old WT mice (25 mo) had a GFR of 3.1 µl/min/g, which was significantly reduced 
from adult WT mice but similar to the GFR of 12-16 w- Ercc1-/Δ mice.  
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To determine the age at onset of proteinuria, the albumin/creatinine ratio (ACR) in urine was 
measured weekly in young WT and Ercc1-/Δ mice (Figure 6B). The ACR increased dramatically 
between 4-5 wks of age in the Ercc1-/Δ mice.  The ACR remained modestly elevated from 5-14 
wks in the Ercc1-/Δ mice, then increased again at 16 wks of age. The ACR in 2 yr-old WT mice 
was significantly increased compared adult WT mice (16 wks) and similar to that of 5-14 wk-old 
Ercc1-/Δ mice. Together, these functional markers indicate that the Ercc1-/Δ mice have progressive 
renal dysfunction that culminates in ESRD by 16 wks of age and mimics functional and 
histopathological changes that occur in the kidney over 2-3 years in WT mice. 
 
Figure 6. Changes in renal function in Ercc1-/Δ and WT mice with aging 
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(A) Glomerular filtration rate (GFR) determined by FITC-inulin clearance from the blood after bolus injection. Data 
reflect the mean GFR in µL/min/g body weight from 3 animals per group ± S.E.M. Asterisk indicates p<0.05 as 
determined by a two-tailed Student’s t-test. (B) Albumin/creatinine (ACR) ratio in the urine of WT and Ercc1-/Δ mice. 
Data reflect the mean values from 3 mice per group ± S.E.M. Asterisk indicates p < 0.05 as determined by a two-tailed 
Student’s t-test. 
2.3.3 Cellular changes in progeroid Ercc1-/Δ mouse kidney mimic natural aging 
With renal aging, endothelial cells become activated, which is detected as an increase in 
intracellular adhesion molecule 1 (ICAM/CD54) expression on the cell surface and can result in 
macrophage infiltration (45). To evaluate this, kidney sections were co-stained with PECAM 
(CD31) to identify endothelial cells and ICAM to detect activation (Figure 7A). Sixteen wk-old 
Ercc1-/Δ mice and old WT (26 mo) mice showed a significant increase in ICAM expression 
compared to adult WT mice not only in the vasculature but also lining Bowman’s capsule and in 
the proximal tubules. Similarly, progeroid and old WT kidneys showed a significant increase in 
macrophage infiltration in and near the glomeruli, as detected by immunostaining for the pan-
leukocyte marker, CD45, and the macrophage marker CD68 (Figure 7B).  
With age-related renal fibrosis there is often an increase in smooth muscle actin (SMA)-
positive cells (30, 31). In 4 mo-old Ercc1-/Δ mice, there was a significant increase in SMA-positive 
cells scattered throughout the tubular interstitium, surrounding Bowman’s capsule and extending 
from arterioles on either side of the glomerulus (Figure 7C). This periglomerular and interstitial 
increase in SMA was also significantly increased in 26 mo-old WT mice.  
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Figure 7. Cellular changes in progeroid Ercc1-/Δ and aged WT mouse kidneys 
(A) Immunofluorescence detection at 200X magnification of ICAM (CD54; green) a marker of endothelial activation 
and tubule injury, PECAM (CD31; red) to identify endothelial cells and Hoescht dye (nuclei; blue) in kidneys from 
16 wk-old WT and Ercc1-/Δ mice and old WT (26 mo) mice. The bottom row shows only ICAM staining (white) at 
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600X magnification. Red arrows show ICAM stained within the glomerulus and red arrowheads show ICAM staining 
at the apical border of the tubules. Changes are quantified in the graph to the right for both PECAM and ICAM. (B) 
Immunofluorescence detection at 200X of CD45 (red), a pan-leukocyte marker and of CD68 (green) a macrophage 
marker and Hoescht dye (blue) in kidney sections. The bottom row at 600X magnification shows the CD45+ and 
CD68+ fluorescence, highlighting a small CD45+ population in 16 wk-old WT (yellow arrow), and a widespread 
CD45+, CD68+ population in the 16 wk Ercc1-/Δ mice and old (26 mo) WT animals, namely macrophage infiltration 
into the glomeruli (arrows) and clustered in infiltrates (arrowheads). Changes in CD68+ fluorescence are quantified 
in the graph to the right. (C) Immunofluorescence detection at 200X magnification of smooth muscle actin (SMA; 
red) a hallmark of aged kidney and the structural protein F-actin staining (green) in kidneys. The bottom row shows 
only the SMA fluorescence at 600X. Arrows highlight intraglomerular SMA+ cells and arrowheads point to 
periglomerular SMA+ cells. Changes in SMA fluorescence are quantified in the graph to the right. For all images, the 
scale bar = 50µm. For all graphs, n=3 animals per group and error bars represent the S.E.M. *p< 0.05, as determined 
by two-tailed Student’s t-test.  
 
2.3.4 Podocyte effacement in progeroid Ercc1-/Δ and old WT mouse kidney 
Due to early onset of albuminuria in Ercc1-/Δ mice, we examined their podocyte structure using 
electron microscopy. Podocytes are highly specialized post-mitotic cells responsible for 
maintaining the filtration barrier and glomerular capillary loop structure (142). The foot processes 
that project from the cell body of podocytes form a highly organized meshwork that acts as a size 
and charge barrier to proteins. Podocyte effacement and thickening of the basement membrane are 
features of renal aging in kidneys of humans and mice (143). Scanning electron microscopy of 
murine kidney sections revealed that 5 mo-old Ercc1-/Δ and aged (25 mo-old) WT mice exhibited 
a severe disruption of podocyte foot interdigitation, necessary for glomerular function (Figure 8A). 
Thin cytoplasmic finger-like projections were also seen extending out of the podocytes in these 
mice, similar to what is observed in aged rats (40). Four wk-old Ercc1-/Δ mice had largely normal 
glomerular ultrastructure with only a few glomeruli displaying mildly disrupted interdigitation of 
the foot processes and largely normal interdigitation of podocyte foot processes by transmission 
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electron microscopy (Figure 8B). At 5 mo of age, there was substantial effacement of podocyte 
foot processes and thickening of the glomerular basement (quantified in Appendix B, Fig 25) in 
Ercc1-/Δ kidneys, similar to changes in old WT mice. Therefore the structural changes observed 
with normal renal aging occur prematurely in Ercc1-/Δ mice.  
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Figure 8. Structural changes in progeroid Ercc1-/Δ and aged WT mouse kidneys 
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(A) Scanning electron micrographs (10,000X) of kidney illustrating progressive podocyte irregularities in mutant and 
WT mice with aging including loss of interdigitation (arrows), thickening of foot processes, and appearance of thin 
cytoplasmic projections (arrowheads). Scale bars = 1µm. (B) Transmission electron micrographs (20,000X) 
illustrating loss of podocyte architecture that is progressive in mutant and WT mice with aging. Arrowheads indicate 
interdigitating foot processes. Arrows indicate effacement and thickening of foot processes. V=vessel. Scale bar = 
500nm. 
2.3.5 Cell turnover in proximal tubules and collecting ducts of Ercc1-/Δ mice 
To investigate the mechanism by which renal degeneration occurs, we measured cleaved caspase-
3, a marker of apoptosis. By immunoblot, there was no difference in the amount of cleaved 
caspase-3 in renal lysates from 5 wk-old Ercc1-/Δ and WT mice (Figure 9A). Remarkably, cleaved 
caspase-3 levels were increased in all adult WT mice but dramatically lower in Ercc1-/Δ mice. 
TUNEL staining of renal sections from 16 wk-old animals confirmed the lack of apoptotic cell 
death in Ercc1-/Δ mouse kidneys (Figure 10). Transcriptional profiling of glomeruli from Ercc1-/Δ 
and aged mice revealed a highly significant correlation and one of the processes dysregulated in 
both normal and accelerated renal aging is apoptosis (131). In contrast, many necrotic proximal 
tubule cells were detected in 5 mo-old Ercc1-/Δ and 28 mo-old WT mice, but not in 5 mo-old WT 
mice (Figure 9B), as is observed in aged rats (40).  
In response to cellular damage or loss, quiescent renal cells can re-enter the cell cycle (144). 
To test if this was the case, WT and Ercc1-/Δ mice were chronically loaded with BrdU beginning 
at 5 wks of age to label replicating cells. At 13 wks of age, after 8 wks of BrdU exposure, there 
were significantly more BrdU-positive cells in kidneys of Ercc1-/Δ mice compared to WT 
littermates (Figure 9C). Co-staining for wheat germ agglutinin (WGA) and BrdU revealed that the 
proximal tubules are the primary site of cell division (Figure 9D) and there is a significant increase 
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Ercc1-/Δ mice compared to WT littermates (Figure 9E). These data indicate that proximal tubule 
cells are particularly sensitive to endogenous DNA damage, which leads to necrotic cell death and 
turnover. 
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Figure 9. Increased cell death and turnover in proximal tubules of progeroid Ercc1-/Δ mice 
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(A) Immunoblot detection of cleaved caspase-3. The blot is representative of data from 3 independent sets of mice. 
(B) Tissue sections (350 nm thick) stained with Toluidine blue. Arrowheads indicate necrotic proximal tubule cells in 
Ercc1-/Δ mice and old WT mice compared to healthy tubule structure with brush border seen in young WT kidney 
(arrow). (C) Immunohistochemical detection of BrdU, a marker of replicating cells, in mice chronically administered 
BrdU 1x per wk x 8 wks total, beginning at 5 wks of age. Images of the cortex and medulla (above the diagonal black 
line in the Ercc1-/Δ image) revealed increased proliferation primarily in the cortex of mutant animals. (D) Co-
immunostaining of kidney sections for BrdU (green) and wheat germ agglutinin (red). Shown are 200X magnification 
images with 600X insets to show higher resolution of proximal tubule structure with characteristic brush border. The 
proliferating cells are localized in the proximal tubules. (E) BrdU uptake was quantified in WT and Ercc1-/Δ kidney 
(n=3 mice per group and 5 sections per animal). Results are expressed as the average number of BrdU-positive nuclei 
per 20X field ± S.E.M. An asterisk denotes that p<0.05, as indicated by a two-tailed Student’s t- test. 
Figure 10. No evidence of apoptotic cells in Ercc1-/∆ kidneys shown by TUNEL stain. 
Kidneys from 18wk irradiated WT mice were stained with TUNEL (green) as a positive ctrl. Arrows indicate positive 
TUNEL stain colocalizing with nuclear stain, DAPI (red). No positively stained nuclei were detected in 16 wk WT or 
Ercc1-/∆ kidneys, supporting the cleaved caspase-3 data in Figure 9. 
2.3.6 Increased senescence in Ercc1-/Δ and old WT kidney 
Genotoxic stress is known to drive cellular senescence (145), which in turn drives age-related 
degenerative changes (146). Senescent cells are characterized by nuclear foci of the 
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phosphorylated histone variant, γH2AX (Ser139) (147), as well as increased expression of p53, 
p21 and p16ink4a and are thought to be largely protective in response cell damage or tissue injury 
(148). To further examine the mechanism by which renal aging is accelerated in Ercc1-/Δ mice, 
senescence markers were measured by immunofluorescence and immunoblot. Kidneys from aged 
WT mice had more γH2AX foci compared to young animals (Figure 11A). Young Ercc1-/Δ mice 
(6 wk) have a modest increase in γH2AX foci compared to littermate controls, which increased 
dramatically by 20 wks of age. This was confirmed by immunoblot, which revealed an 
approximately 2-fold increase in γH2AX protein in renal lysates of Ercc1-/Δ and aged mice 
compared to young WT animals (Figure 11B). p53 protein expression was also substantially 
increased in Ercc1-/Δ mice compared to WT littermates and increased with age. P53 expression 
was also dramatically increased in the kidneys of aged WT mice. A similar pattern of expression 
was observed for p16 (Figure 11B). P21 levels were also elevated in aged WT mice compared to 
younger animals and peaked at 3 mos in Ercc1-/Δ mice. Finally, increased senescence-associated 
β-galactosidase activity was detected in 9 and 15 wk-old Ercc1-/Δ mice compered to WT littermates 
(Figure 12). These data provide strong evidence that endogenous DNA damage promotes cellular 
senescence in the kidney and this contributes significantly to renal aging even in repair competent 
organisms. 
As a final comparison between old and progeroid kidneys, we re-analyzed the transcription 
profiles recently created from glomeruli of 96 wk-old WT mice and 14 wk-old Ercc1-/Δ mice (131). 
In our analysis, the Ercc1-/Δ and aged mouse profiles were compared to that of 14 wk-old adult 
WT mice. 300 genes were discovered to be differentially expressed in Ercc1-/Δ mice, defined as 
≥1.5-fold change and p<0.05 (Figure 11C and gene list in Table 4 in Appendix A) and 147 genes 
were differentially expressed in aged mice.  69 genes overlapped between the Ercc1-/Δ mice and 
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old WT mice, which was highly significant (p<2.2x1016). This extends the strong parallels between 
accelerated renal aging in Ercc1-/Δ mice and normal renal aging to molecular commonalities. 
Pathways discovered to change with aging include immune regulation, which was confirmed in 
Figure 7, cell fate, confirmed in Figure 9 and 10, and metabolism.  
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Figure 11. Increased cell senescence in old and progeroid Ercc1-/Δ mouse kidneys. 
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(A) Immunofluorescence detection of γH2AX (200X, with higher mag insets to show foci), indicating a modest 
increase in foci in 6 wk Ercc1-/∆ and 30 mo-old WT kidneys compared to young WT, and a large increase in foci in 
20 wk Ercc1-/∆ kidneys compared to young WT. γH2AX staining is red, DAPI highlights nuclei in blue. (B) 
Immunoblot detection of senescence markers γH2AX, p21, p53and p16INK4a in whole kidney lysates. Tubulin was 
used as a loading control. The blot shown is representative of data obtained from 3 sets of mice. (C) Gene expression 
analysis of the published kidney dataset GSE43061. There were 369 transcripts differentially expressed in 14 wk 
Ercc1-/∆ kidneys compared to 14 wk WT controls (≥1.5 fold change and p<=0.05) and 216 transcripts differentially 
expressed between 96 wk WT kidneys and the 14 wk WT control group. 69 genes overlapped between the two profiles, 
which is highly unlikely to be due to chance (p<2.2x106). The overlapping gene names are included in supplementary 
table 5 in Appendix C.  
Figure 12. Senescence-associated-β-galactosidase (SA-β-gal) increase in Ercc1-/∆  Kidneys 
Frozen kidney sections from 9, 15 wk WT and Ercc1-/∆ mice were stained to detect senescence-associated 
β−galactosidase (SA-β−gal) activity. SA-β−gal staining (blue) was increased in Ercc1-/ ∆ kidneys at both 9wks and 
15wks. In progeroid kidneys, as compared to 9 wks, there is a slight decrease of stained cells at 15 wks, possibly due 
to tubule cell loss and/or replacement, as detected in Figure 8. 
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2.4 DISCUSSION 
Renal function declines with age leading to a decrease in GFR, glomerulosclerosis, macrophage 
infiltration and fibrosis (30, 31, 45). The underlying cause of age-related nephropathy is largely 
unknown. Herein, we demonstrate that the functional, structural, histological, cellular and 
molecular changes seen with renal aging in WT mice is recapitulated in DNA repair-deficient 
Ercc1-/Δ mice, albeit the onset is accelerated 5-6 fold. This provides strong evidence that 
endogenous DNA damage, which accumulates in the kidney with aging (149), contributes to age-
related nephropathy.  
FAN1 codes for a DNA repair nuclease similar to ERCC1-XPF that is required for the repair 
of DNA interstrand crosslinks and other endogenous lesions (105). FAN1 disruption in fish causes 
apoptosis and renal cysts. FAN1 mutations in humans cause karyomegalic interstitial nephritis 
characterized by cystic dilation of renal tubules and widespread interstitial infiltrates and fibrosis 
(105). These studies further demonstrate that failure to repair spontaneous, endogenous DNA 
damage can lead to CKD and other degenerative changes associated with age-related nephropathy.  
To determine how DNA damage promotes renal aging, markers of apoptosis, cell senescence, 
regeneration and necrosis were measured. Cleaved caspase-3 protein expression does not correlate 
between normal and accelerated aging. However, there is evidence of necrosis and regeneration in 
proximal tubule epithelia. Importantly, senescence markers γH2AX, p21, p53 and p16 were 
strongly up regulated in Ercc1-/Δ mice. This suggests that cellular senescence, a programed cell 
fate associated with aging (146), plays a key role in promoting age-related nephropathy in response 
to endogenous genotoxic stress. Notably, p16, p53 and γH2AX levels were greatest in old WT 
mice, strongly supporting the conclusion that genotoxic stress-induced cellular senescence plays a 
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causal role in normal age-related nephropathy. Finally, transcriptome analysis of isolated 
glomeruli revealed highly significant overlap in gene expression changes in Ercc1-/Δ old WT mice 
and point changes in immune regulation, cell fate and metabolism as contributing to renal aging 
in both natural and accelerated aging.  
The urinalysis and structural studies indicate that podocyte foot-process thickening is one of 
the first changes detected in the Ercc1-/Δ mice (Figure 2 and 4). It begins at 4 wks of age and 
progresses. The glomerular basement membrane also thickens. Podocytes are exposed to multiple 
sources of stress, including distending forces from high glomerular blood flow (27) and depend 
primarily upon mitochondrial oxidative respiration for energy (150), a source of damaging reactive 
oxygen species. Oxidative damage to macromolecules and organelles is cleared by autophagy, 
since podocytes are post-mitotic and not replaced. If the damage is overwhelming, podocytes are 
lost, which correlates strongly with ESRD (27).  
Following podocyte injury at 4 wks of age Ercc1-/Δ mice, at 8 wks, there is evidence of vascular 
and proximal tubule injury, including upregulation of ICAM, progressive increase in SMA+ cells, 
macrophage infiltration and proximal tubule epithelial cell necrosis and proliferation. In a toxin 
model, podocyte injury induces proliferation of renal tubule epithelium (12). Proximal tubule cell 
necrosis is seen in aged rats (40). Collectively, these studies suggest that podocytes are particularly 
susceptible to damage with aging, leading to loss of glomerular function, which in turn triggers 
other, subsequent renal pathologies. 
In summary, data from both the progeroid model and aging WT mice indicate that endogenous 
DNA damage can drive renal aging. Glomerular injury appears to precede renal tubule necrosis, 
fibrosis and macrophage infiltration. The Ercc1-/Δ mice offer a highly rapid and accurate 
spontaneous model of aging-related degenerative changes leading to CKD and ESRD. 
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3.0  PODOCYTE INJURY CAUSES SUBSEQUENT KIDNEY DISEASE IN ERCC1 
DEFICIENT MOUSE MODEL 
Because of the increasing elderly population, there is rising incidence of CKD and ESRD. Very 
little is known about the mechanism of or the contributions of various kidney cell types to causing 
aging nephropathy(28, 31, 118).  It is difficult to separate out age-related kidney changes from 
other aging diseases such as diabetes or cardiovascular disease, which affect kidney function. Here, 
I provide mechanistic information as to the progression of CKD in the Ercc1 deficient mouse, as 
well as evidence of the role of the glomerular podocyte in causing this disease. The Ercc1-/∆ mouse 
model is an accurate tool in which to study the progression of age-related renal senescence in an 
accelerated manner. Podocyte injury, characterized by effacement of foot processes, an increase 
in IKK, and induction of autophagy, occurs at 4 weeks, along with an elevated albumin-creatinine-
ratio (ACR). By 8 wks of age, autophagic flux in podocytes becomes impaired, chronic activation 
of the transcription factor, NF-κB, begins in podocytes, ACR rises significantly, glomerular 
filtration rate (GFR) decreases, and tubule injury occurs. This is followed by other global age-
related kidney changes such as fibrosis and macrophage infiltration. Using a podocyte specific and 
a proximal tubule specific knock-out of Ercc1, evidence is provided here that damage 
accumulation in the Ercc1 deficient podocyte, but not the Ercc1 deficient proximal tubule, is the 
primary driving force in decline in kidney function, loss of structure, and early death. Finally, in 
vitro work in podocytes provides evidence that the IKK- NF-κB pathway and autophagy are 
intertwined, and that dis-regulation of each could be playing a role in age-related kidney disease.  
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3.1 INTRODUCTION 
Renal function declines in adults and end stage renal disease (ESRD) occurs at peak 
incidence in the elderly. Glomerulosclerosis is the main cause of ESRD and this is accompanied 
by a decrease in glomerular filtration rate(32, 151, 152). Loss of kidney function with age is also 
an independent risk factor for cardiovascular disease and mortality(151). The elderly are at greater 
risk for glomerular disease. The aging population is rising and evidence of kidney functional 
decline is present even in otherwise healthy individuals. Also, the aged kidney is much more 
susceptible to injury and disease(32). Still, little is known about the mechanism of changes that 
occur in the aging glomerulus and the role of specific cell types in driving these age-related 
pathologies.  
Podocyte loss occurs during glomerular disease and with aging, and there is little or no 
evidence that podocytes are replaced by proliferation or by bone marrow or parietal cells(6). It is 
known that this podocyte injury and loss predicts the severity of disease and eventual ESRD(151), 
but little is known about the mechanism of such injury and the role it plays in causing subsequent 
pathologies in the glomerulus, tubules, and interstitium.  The cellular “aging” phenotype in patients 
with renal disease may determine what therapies may work and may be completely different than 
what is appropriate for a younger patient.  
  
3.1.1 The aging glomerulus 
Evidence from aging research in humans and animals show that 30% of glomeruli are lost 
by 75 years of age and the remaining have limited filtering capabilities. These studies suggest that 
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many factors contribute to aging nephropathy such as hypertension, obesity, and previous kidney 
injury(28). It is then difficult to tease out the contribution of inherent kidney damage in causing 
aging nephropathy, as well as to elucidate the role of the various kidney cells. Glomerular diseases 
associated with old age include membranous nephropathy, minimal change disease and focal 
segmental glomerulosclerosis. It is estimated that at least 90% of ESRD is subsequent to chronic 
glomerular damage and ESRD is strongly associated with aging(6, 33). Podocyte loss and 
glomerulosclerosis increases with age(13). Various factors can affect and accelerate this process, 
but the problematic outcome seems to remain the same. Loss of podocytes and failure of the 
glomerulus to compensate leads to age-associated kidney damage. While there is much in the way 
of describing age-associated glomerulosclerosis and other kidney pathologies, very little is known 
about the mechanism or the contributions of certain compartments and cell types.  
 
3.1.2 NF-κB and autophagy  
While there is a wealth of evidence in various cell types of a complex relationship between 
the NF-κB and autophagy pathways(153-158), very little is known about this relationship during 
aging, and even less is known about this relationship in the podocyte. It is clear from the literature 
that the IKK complex and NF-κB can enhance expression of autophagy proteins in a context 
specific manner, and that autophagy can degrade all subunits of IKK to negatively regulate the 
pathway after autophagy cycles through(157). However, it has also been shown that NF-κB 
activation can cause an increase in autophagy inhibitors such as Bcl-2/xL and inhibit activators 
such as reactive oxygen species (ROS)(157). Eventually with aging, there is a decrease in Beclin 
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1 and evidence of impairment of autophagic degradation. It is also known that there is chronic NF-
κB activation in some tissues with aging(157, 158).  Meng et al(159) showed that defective 
autophagy by Atg 7 knock-out in the hypothalamus caused inflammation and NF-κB activation, 
which resulted in a changed metabolism and weight gain in mice. The effects were reversed in 
mouse that also had a brain-specific IKKβ knock out. Along these lines, many investigators(155, 
156)) have shown that the members of the IKK complex and active IKKβ are down regulated by 
autophagy, so it would make sense that defective autophagy could result in sustained levels of 
active IKK and subsequent sustained NF-κB activation. 
Podocytes depend on a high level of autophagy to deal with the oxidative damage and stress 
that can build up during its long-lived, post-mitotic life, and also use autophagy to fuel their protein 
secretion and trafficking(5). This leads to the hypothesis that the dis-regulation of autophagy and 
NF-κB signaling could be related and play a role in propagating podocyte injury in the Ercc1-/∆ 
mouse model of accelerated kidney aging.  
 
3.1.3 The Ercc1-/∆ mouse model of accelerated renal aging 
As we have previously shown, the Ercc1-/∆ mouse is a valuable tool in which to study the 
process of aging in the kidney in a timely manner. The transcriptional profile of the Ercc1-/∆ kidney 
glomerulus and a naturally aged glomerulus share many differential gene expression changes when 
compared to young adult WT, including genes involved in inflammation, cell fate, and 
metabolism(131). These mice have a maximum lifespan of 7 months and develop widespread 
aging pathologies(102), including neurodegeneration, sarcopenia, and liver(113) and kidney 
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disease. As presented in chapter 2, mice develop albuminuria in the first 1-2 months of life and 
podocyte injury, followed by a decrease in GFR, tubule injury, fibrosis, and macrophage 
infiltration. Kidneys also show up-regulation of senescence markers, p16, p21, and SA-
β−galactosidase activity. Histology studies demonstrate thickening of capillary loops, focal 
glomerulosclerosis, thickening of GBM and TBM, and widespread interstitial fibrosis.  By creating 
cell specific knockouts of Ercc1 in the kidney, it is possible to determine the contribution of 
various cell types in causing age-related kidney disease and to then study the mechanism by which 
this occurs in order to develop therapies for age-related CKD. Because podocytes are post-mitotic 
and loss of podocytes correlates with ESRD, could podocyte damage during the aging process be 
responsible for subsequent kidney injury and disease? Or, is it proximal tubule injury due to Ercc1 
deficiency that is primarily responsible for the aging pathologies and decrease in function?  
The work here tests the hypothesis that podocyte injury causes the subsequent kidney 
pathologies seen in the Ercc1 deficient mouse model of accelerated kidney aging, and possibly in 
natural aging as well. In order to test this hypothesis, it was necessary to first determine the time 
course and nature of podocyte injury as it relates to other age-related changes in the Ercc1-/∆ mouse 
kidney. Secondly, a genetic approach was employed to determine the role of inherent podocyte 
injury caused by Ercc1 deficiency in causing age-related chronic kidney disease. Specifically, a 
podocyte-specific knock out of Ercc1 was created using a Podocin-cre mouse(160),  crossed into 
a mouse with a floxed Ercc1 allele, allowing Ercc1 to be knocked out of podocytes only. Since 
proximal tubule injury also occurred in the Ercc1-/∆ mouse kidney, a proximal tubule-specific 
Ercc1 knock out was created, using a gamma-glutamyltransferase-cre (γ-GT-cre) mouse(161). 
The data presented here provide key insight into cellular and molecular pathways that should be 
targeted for development of effective therapies for age-related CKD.  
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 3.2 MATERIALS AND METHODS 
Animal Care and Experimentation 
Animal work was approved by the University of Pittsburgh and Scripps Florida Institutional 
Animal Care and Use Committees and is in accordance with NIH guidelines for humane care of 
animals. Ercc1-/Δ mice were bred and genotyped as previously described (126). All mice were in a 
congenic f1 background generated by crossing inbred FVB/n and C57Bl/6 mice. For the podocyte 
specific knock out of Ercc1, a C57/BL6 mouse expressing Cre recombinase under the NPHS2 
(podocin) promoter (Pod-cre+/-, Jackson Laboratories, Bar Harbor, ME) and heterozygous knock-
out of Ercc1 (Ercc1+/-)  was crossed with a FVB/n mouse carrying  one loxP-flanked Ercc1 allele, 
termed “conditional,” (Ercc1+/c). Podocyte specific knock-out mice were bred and genotyped as 
above, displaying a genotype of Pod-cre+/-; Ercc1-/c.   For the proximal tubule-specific knock out, 
a C57/BL6 mouse expressing cre recombinase under the Ggt1, gamma-glutamyltransferase 1, 
promoter (γGT-cre +/-, Jackson Laboratories, Bar Harbor, ME), Ercc1+/-, was crossed with a 
FVB/n mouse carrying a loxP-flanked Ercc1 allele, termed “conditional,” (Ercc1+/c). Proximal 
tubule-specific knock out mice were bred and genotyped as above, displaying a genotype of γGT-
cre+/-; Ercc1-/c.  In order to monitor NF-κB activation, NF-κBEGFP mice, containing the eGFP 
reporter under the control of NF-κB responsive elements(162), were crossed into Ercc1+/- and 
Ercc1+/∆  lines to create an NF-κBEGFP; Ercc1-/∆ mouse. NF-κBEGFP young and old “WT” mice 
were used as controls.  
Kidney perfusion and processing for ultrastructural analysis 
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For EM, the kidneys of euthanized animals were cleared of blood by perfusion with PBS at 3 
mL/min via cardiac puncture then perfuse-fixed or immersed in 2.5% glutaraldehyde in PBS and 
processed as described previously (113). 350 nm sections were cut and stained with Toluidine Blue 
for light microscopy analysis. Ultrathin sections were digitally imaged using a JEOL JEM 1011 
transmission electron microscope (Peabody, MA) at 80 kV fitted with a side mount AMT 2k digital 
camera (Advanced Microscopy Techniques, Danvers, MA).  
Immunofluorescence analyses  
IF was performed on frozen kidney sections as previously described (113). Briefly, kidneys were 
fixed in 2% paraformaldehyde in PBS for 2-4 hrs followed by 30% sucrose at 4°C overnight, then 
frozen in liquid N2-cooled isopentane and sectioned (7µm thick) on a Microm™ HM 550 cryostat 
(Thermo Scientific; Waltham, MA).  Primary antibody was incubated at room temperature for 1 
hr (goat anti-CD68, Santa Cruz Biotechnology, Inc., Santa Cruz, CA; anti-SMA:Cy3, Sigma, St. 
Louis, MO; rat anti-CD45 or rat anti-CD31 (PECAM) both from BD Pharmingen, San Jose, CA; 
or hamster anti-ICAM, BD Biosciences, San Jose, CA) all at a dilution of 1:100. Sections stained 
with rabbit anti-LC3 (1:200), Novus, Littleton, CO; guinea pig anti-p62 (1:100), Fitzgerald, Acton, 
MA; guinea pig anti-nephrin (1:100), Fitzgerald, Acton, MA; rabbit anti-pS6 (1:50), Cell 
Signaling, Danvers, MA; rabbit anti-IKK-β (1:100), Νοvus, Littleton, CO; rat anti-KIM-1 (1:100), 
R&D systems, Minneapolis, MN were incubated overnight at 4oC. The fluorescent secondary 
antibodies (Invitrogen, Eugene, OR; Jackson ImmunoResearch Laboratories, West Grove, PA), 
raised against the origin of each primary antibody, were added for 1 hr in the dark at room 
temperature. Nuclei were stained with DAPI and mounted with gelvatol under glass coverslips. 
Images were acquired using an Olympus Fluoview 1000, inverted confocal microscope or the 
Nikon 90i scanning microscope for whole section fluorescence image quantification. 
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Albumin/creatinine ratio measurement 
Urine was collected from mice weekly as described in Chapter 2 and albumin levels quantified 
using the mouse Albumin Elisa Kit (Bethyl Laboratories, Montgomery, TX). Albumin levels were 
normalized to creatinine levels using the mouse Creatinine Urine Assay Kit (Cayman Chemical, 
Ann Arbor, MI). For each time point, an n=3 was used and the average albumin-creatine-ratio 
(ACR) values were plotted ± S.E.M.. Significance was calculated using the Student’s two tailed t-
test; *p < 0.05.  
Determination of GFR 
GFR was measured using FITC-inulin clearance by modified protocol (132). Briefly, mice (n=3 
per group) were given a bolus injection of a 2.5% FITC-inulin (Sigma-Aldrich, St. Louis, MO) in 
HEPES retro-orbitally (2 µl per g body weight). Blood was collected from the tail tip before 
injection and 3, 5, 7, 10, 15, 20 and 40 min post-injection. Plasma was isolated and samples were 
diluted 1:10 in 0.5M Hepes. FITC fluorescence was measured in duplicate for each animal using 
a Perkin Elmer EnVision 2104 Multilable Reader. GraphPad Prism was used to plot FITC-inulin 
concentration using a two-phase exponential decay model. GFR was normalized using body 
weight and expressed as µl/min/g BW.  
Cell culture of immortalized podocytes and glomerular isolation from kidney 
Conditionally immortalized mouse podocytes (MP-1) cells were generously provided by Dr. 
Valerie Schumacher (Harvard Medical School). These podocytes were originally derived from the 
temperature-sensitive SV40 large T antigen transgenic mouse by subcloning outgrowths of 
glomeruli isolated using standard sieving and magnetic bead isolation(163). This podocyte cell 
line grows at 33oC and in the presence of IFN-γ, and becomes differentiated and post-mitotic after 
switching to 37oC with 10-14 days of culture. Cells were grown on 0.05mg/mL collagen IV 
 61 
(Millipore, Temecula, CA) substrate and displayed primary and secondary branching and high 
levels of nephrin, similar to in vivo podocytes. Isolated glomeruli culture experiments were 
performed with glomeruli from freshly resected mouse kidneys, isolated by standard differential 
sieving as described previously(164, 165). Briefly, freshly isolated kidney cortex was minced into 
approximately 1 mm sized pieces in DMEM medium (Life Technologies, Grand Island, NY) plus 
5% fetal bovine serum (FBS). Cortex pieces were then incubated at 37oC for 30 min. in 1mg/mL 
collagenase II (Worthington, Lakewood, NJ) in DMEM medium. The digested suspension was 
then passed through a 100 µm sieve, followed by a 70 µm sieve to remove large tissue chunks and 
connective tissue. This suspension was then passed through a 40 µm sieve, and the material on top 
of the filter (>40 µm) was washed and used for glomerular culture. Few tubules remained and 
glomeruli were identified by nephrin expression during imaging experiments. Glomeruli were 
cultured overnight on 0.05mg/mL collagen IV (Millipore, Temecula, CA) with or without 5nM 
bafilomycin A (Sigma-Aldrich, St, Louis, MO), and fixed with 2% paraformaldehyde in PBS for 
staining and imaging. Images were acquired using an Olympus Fluoview 1000, inverted confocal 
microscope. Autophagic flux studies were performed using either 5nM bafilomycin A as 
mentioned above, or 25 µM chloroquine (Sigma-Aldrich, St. Louis, MO). For IKK inhibition, 
300nM IKKi VII (EMD Millipore, Billerica, MA) was added to the culture medium for 3 or 6 hrs. 
For constitutively-active IKK expression, cells were transfected overnight with 100ng of the 
FLAG-IKK-2 plasmid (Addgene, originally from Dr. Anjana Rao, Scripps, La Jolla, CA) into the 
center well of a Mattek dish, using 0.2 uL of Lipofectamine 2000 (Life Technologies), on day 8 
of differentiation. Experiments were performed and cells were fixed on day 10, 2 days post 
transfection. Transfection was confirmed with an anti-mouse FLAG antibody (clone M2, 1:100, 
Sigma-Aldrich, St. Louis, MO).  
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3.3 RESULTS 
3.3.1 Time course of podocyte injury and age-related kidney pathologies in the 
Ercc1/∆ mouse 
Podocyte injury is detected as early as 4 wks in the Ercc1-/∆ mouse model, followed by endothelial 
cell activation, proximal tubule injury, macrophage infiltration, and fibrosis. Podocytes are post-
mitotic and therefore must deal with accumulated damage or die during the aging process, where 
there is little or no evidence of replacement. Loss of podocytes correlates with ESRD. It is then 
possible that podocyte injury in the Ercc1-/∆ mouse model and during natural aging is largely 
responsible for causing subsequent pathological changes, such as tubule injury and macrophage 
infiltration. First, it was necessary to determine the time course of major changes that occur in 
podocytes with aging in the Ercc1-/∆  kidney, and how they relate to the time course of global 
kidney changes that occur.  
3.3.1.1 Age-related chronic NF-κB activation occurs in the podocytes of Ercc1/∆ mice  
Since increased NF-κB activation occurs with aging(166-168), it is possible that dis-
regulated NF-κB signaling could be responsible for propagating the inflammatory and senescence 
changes detected in Chapter 2. Therefore, we determined whether NF-κB activation, previously 
found in both old WT and 3 month old Ercc1-/∆ kidneys (but not young WT) (168), occurs 
chronically in Ercc1-/∆  kidneys and in which cell type(s). To achieve this, kidneys from old NF-
κBEGFP mice, as well as 1, 2, 3, 4, and 5 mo old Ercc1-/∆ ; NF-κBEGFP mice and their NF-κBEGFP 
control littermates were examined. These mice contain the EGFP reporter under the control of NF-
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κB responsive elements(162), and therefore display eGFP fluorescence in cells where NF-κB is 
activated.  No GFP-positive cells were detected in young WT mice. However, low levels of GFP 
were detected in the glomerulus by 2 months of age in the Ercc1-/∆ kidney and continued through 
4 months of age, disappearing at 5 months, when severe cellular loss and overt pathologies 
occurred (Figure 13A). GFP fluorescence in the cortex was quantified in whole sections using a 
Nikon 90i, scanning microscope, and GFP levels were confirmed to increase significantly by 2 
months of age, peaking at 3 months. Significant GFP-positive glomeruli were also detected in 2 
year old WT kidneys (Figure 13B). This chronic NF-κB activation in the glomerulus was 
confirmed (n=3 mice), and the trend was the same, with varying levels of fluorescence between 
mice. 
 In order to determine in which cell type this chronic NF-κB activation was occurring, 
kidneys were stained with an antibody against nephrin, a podocyte marker (Figure 13C). Nearly 
all of the GFP fluorescence co-localized in single confocal sections with nephrin. Nephrin levels 
also decreased significantly over time, indicating a functional breakdown of the podocyte filtration 
barrier.  Of note, GFP fluorescence did not ever co-localize with endothelial or tubule markers.  
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Figure 13. Chronic NF-κB activation in podocytes in the Ercc1-/∆ and old WT kidney 
(A) Epifluorescent images of NF-κB-eGFP; Ercc1-/∆  and their age-matched controls at 1, 2, 3, 4, and 5 months of age 
show chronic NF-κB activation in glomeruli from 2-4 months. (B) Representative image of whole section, high 
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resolution fluorescence image and quantification of GFP fluorescence. NF-κB activation begins at 2 months, peaks at 
3 months, and eventually decreases to null right before death. Old WT kidneys also display high levels of glomerular 
NF-κB activation. (C) Single optical section confocal images of 2-4 months old NF-κB-eGFP; Ercc1-/∆  kidneys, co-
stained for podocyte marker, nephrin and endothelia cell marker, CD31 (PECAM). eGFP co-localizes primarily with 
nephrin and never with PECAM, SMA, or CD68 (Fig 10), providing evidence that the podocyte is the main cell type 
where NF-κB is chronically activated in the accelerated aging model and with natural aging. Nephrin expression 
decreases with time in the Ercc1-/∆  kidney podocyte, indicating functional breakdown.  
 
The work in Chapter 2 provided evidence of up-regulation of ICAM, smooth muscle actin, 
and CD68 (macrophage infiltrates) at 16 weeks of age in the Ercc1-/∆  kidney, as well as with 
naturally aged WT mice.  In order to determine whether chronic NF-κΒ activation in the podocyte 
is upstream or downstream from these other aging pathologies, the time course of up-regulation of 
these markers was determined, using high-resolution whole slide imaging. The age of onset of the 
aging markers was compared to the onset of chronic NF-κB in podocytes, relative to WT controls. 
Representative confocal images show an increase in ICAM in capillaries and the apical border of 
tubules at 2-4 months in the Ercc1-/∆  kidney, NF-κB-eGFP kidneys compared to controls. 
Quantification of whole sections shows that the onset of up-regulation occurs early, by 1 month of 
age in the capillaries (Figure 14A). It is likely that initial podocyte injury affects the endothelium, 
located on the other side of the GBM, and causes activation. Quantification of smooth muscle actin 
(Figure 14B), show that SMA up-regulation over controls begins at 2 months of age, around the 
same time NF-κB becomes chronically active in podocytes. CD68 quantification provides 
evidence that macrophage infiltration occurs after NF-κB activation in podocytes (Figure 14C). 
Therefore, it is possible that podocyte injury and chronic NF-κB activation may contribute to the 
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other inflammatory and fibrotic changes detected both in the accelerated aging model and with 
natural aging.  
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 Figure 14. Time course of chronic NF-κB activation in podocytes in relation to other changes 
(A) Representative confocal images of NF-κB-eGFP; Ercc1-/∆  and their age-matched controls, stained for 
PECAM(red), ICAM(blue), and DAPI (white) in 2-4 mo old kidneys. Quantification of whole slides using high-
resolution scanning epi-fluorescence imaging shows age of onset of ICAM increase in progeroid kidneys to be at 1 
month of age. (B) Representative confocal images of NF-κB-eGFP; Ercc1-/∆  and their age-matched controls, stained 
for smooth muscle actin (SMA), and DAPI (blue or white). Quantification of whole slides shows age of onset of SMA 
increase to begin at 2 months of age. (C) Representative confocal images of NF-κB-eGFP; Ercc1-/∆  and their age-
matched controls, stained for CD45 (pan leukocyte, red), CD68 (macrophage, blue). In progeroid kidneys, virtually 
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all CD45 co-localizes with CD68 fluorescence (purple), indicating immune cells are primarily macrophages. 
Quantification of whole slides shows age of onset of macrophage infiltration to begin at 3 months of age.  
3.3.2 Chronic NF-κB activation onset coincides with autophagic flux impairment and 
induction of kidney pathologies at 2 months 
Podocytes depend on a high rate of basal autophagy for their health and during times of stress, and 
it is known that autophagy impairment occurs with age and in CKD(5, 27). In agreement with 
evidence from the literature, isolated glomeruli from young WT mice display high levels of active 
autophagy, whereas glomeruli isolated from 2.5 yr WT mice display accumulation of LC3-positive 
and p62 (a protein constitutively degraded by autophagy)-positive puncta and less active 
autophagy (Appendix D, Figure 27). This leads to the question as to whether autophagy induction 
occurs at an early time point in the accelerated aging model, as well as to when autophagic flux 
impairment occurs during the aging nephropathy process.  
Imaging was employed to measure levels of the autophagy markers, LC3 and p62, in the 
glomerulus. If functional autophagy is induced, LC3 fluorescence should increase, while p62 
levels remain low or decrease due to increased degradation. As autophagic impairment progresses, 
LC3 puncta accumulate, and p62 levels increase as well, due to lack of effective degradation.   
LC3 was shown to increase as early as 4 weeks in the Ercc1-/∆  glomerulus and LC3 puncta 
continued to increase with age (Figure 15a). P62 levels at 4 weeks show a slight decrease, and 
therefore the increased LC3 most likely represents functional autophagy induction in the 
glomerulus. However, by 8 weeks (Table 3), p62 levels increase above controls and continue to 
remain high, often localized to puncta, as shown at 12 weeks (Figure 15b). IKK levels show a 
slight increase at 4 weeks (Table 3) and continue to increase with age, often localized to puncta 
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(Figure 15c). Finally, it has been shown in mouse embryonic fibroblasts that IKK-β can cause 
increased mTOR activation by inhibiting the TSC complex(169). pS6 kinase, a marker of mTOR 
activation, is increased by 2 months (Table 3), in the Ercc1-/∆  glomerulus, and remains high  to 4 
months (Figure 15d).  
There is extensive evidence in other cell types and tissues that IKK and NF-κB activation 
are tightly involved with autophagy regulation and vice versa(153-155, 157). Further, it has 
recently been shown that defective autophagy in the hypothalamus in mice causes inflammation 
and obesity through IKK-beta-NF-κB pathway(159). If the dysregulation of these pathways is 
related, the timing of autophagy impairment and chronic NF-κB activation in podocytes during 
aging should coincide. Table 3 provides a summary of all markers measured during the aging 
process in the Ercc1-/∆  kidney and old WT. Markers measured in the glomerulus specifically are 
shown in red. From 1-2 months (Table 3, yellow), there is evidence of a large phenotypic shift in 
podocytes, where autophagy becomes defective and chronic NF-κB activation occurs in 
podocytes, followed by onset of global kidney pathologies and functional indications of CKD, 
indicated by large increase in ACR and decrease in GFR. This data leads to the question as to 
whether inherent podocyte injury, due to accumulating damage, could cause the age-related CKD 
observed in the Ercc1 deficient mouse kidney and possibly during natural aging.  
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Figure 15. Glomerular autophagy and IKK changes in the Ercc1-/∆ kidney  
(A) Representative confocal images show LC3 increase by 4wks in the Ercc1-/∆ glomerulus, maintained with increased 
puncta at 12 wks, compared to WT controls. (B) p62 levels remain low at 4wk during LC3 increase, indicate functional 
induction of autophagy. Subsequent increase in glomerular p62 levels, present in puncta, indicate autophagy 
impairment. (C) IKK increase shown at 16 wks in the Ercc1-/∆  glomerulus, compared to WT controls. (D) pS6 
increase, shown at 16 wks in the Ercc1-/∆  glomerulus, indicate increased mTOR activation.  
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 1 mo 2 mo 3 mo 4 mo Old WT 
LC3 + + + (puncta) + (puncta) +(puncta) 
p62 - + + + + 
IKK + (slight) + + + + 
NF-κB 
Activation 
0 + + + + 
pS6 0 + + + + 
SMA 0 + + + + 
CD68 0 0 + + + 
ICAM + + + + + 
GFR 0 - - - - 
ACR + ++ ++ +++ + 
Table 3. Summary of age-related changes in the Ercc1-/∆ kidney.   
Autophagic flux impairment coincides with chronic NF-κB activation. Markers were quantified by either confocal or 
whole slide scanning, n=3. “0” denotes no change from young WT control. “+” denotes an increase compared to young 
WT controls. “-“ denotes a decrease compared to young WT controls. Changes measured in the glomerulus 
specifically are written in red font. Major transition occurs from 1-2 months (highlighted in yellow). 
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3.4 INHERENT PODOCYTE DAMAGE DUE TO ERCC1 DEFICIENCY CAUSES 
SUBSEQUENT TUBULE INJURY, CHRONIC KIDNEY DISEASE, AND DECREASED 
LIFESPAN  
3.4.1 Functional Changes in Podocyte specific knock-out and Proximal Tubule specific 
knock-out of Ercc1 
Since there is evidence of podocyte injury by 4 weeks in the Ercc1-/∆  kidney, before other 
pathological changes become apparent, it is possible that inherent damage in the podocyte, due to 
ERCC1 deficiency, is causing the subsequent global kidney pathologies, impaired function, and 
perhaps decreased lifespan. In order to test this, a podocyte specific Ercc1 knock-out, (Ercc1-pod-
KO) was created. Because there is also evidence of subsequent proximal tubule injury and 
replacement (discussed in Chapter 2) in the Ercc1-/∆  kidney, and since there is much controversy 
over the role of the podocyte versus the proximal tubule in preventing albuminuria(170), a 
proximal tubule specific knock-out was also created using a gamma-GT-cre mouse (Ercc1-PT-
KO). The podocyte specific Ercc1 knock-out has a significantly reduced average lifespan of 37 +/- 
9.7 weeks (Figure 16A), which is slightly longer than the Ercc1-/∆  mouse (16 +/- 2.3), possible 
due to additional systemic effects in the Ercc1-/∆  mouse or variability in the degree of knock out 
in the Ercc1-pod-KO (Figure 1). Currently, 100% of the Ercc1-PT-KO knock-out group is alive 
(has not died of natural causes), at 11 months of age, with no overt pathological phenotype. Urine 
albumin creatinine ratio (ACR) was determined for both cohorts. The Ercc1-pod-KO had a 
significantly elevated ACR compared to controls by 12 weeks of age, and the ACR decreased 
dramatically until death (Figure 16B). The Ercc1-PT-KO never displayed elevated ACR above 
 74 
controls, even up to 48 weeks of age (Figure 16C). Next, the glomerular filtration rate (GFR) was 
determined by FITC-inulin clearance. At 8 months of age, the Ercc1-pod-KO mice had a severe 
decrease in GFR to levels compared to control mice (Figure 16D). At 7 months of age, the Ercc1-
PT-KO did not display any decrease in GFR compared to controls (Figure 16E). These data 
demonstrate that Ercc1 deficiency in podocytes, but not proximal tubule cells, can cause a 
decreased lifespan, extreme albuminuria, and a large decrease in the GFR. In conclusion, podocyte 
injury due to unrepaired, endogenous DNA damage causes a significant decline in renal function, 
culminating in end stage renal disease (ESRD).  
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Figure 16. Podocyte, but not proximal tubule specific knock-out of Ercc1, results in impaired kidney Function 
and decreased lifespan.  
A) Kaplan-Meyer curve compares lifespan of WT (blue), Ercc1-/c, heterozygous for the floxed Ercc1 as a control 
(green), Ercc1-Pod-KO (red), and Ercc1-PT-KO (orange, *=cohort has not died of natural causes yet, at the age of 11 
months). (B) Urine albumin-creatinine ratio (ACR) of the Ercc1-Pod-KO mice compared to Pod-cre and Ercc1 -/c 
controls.  Data reflect the mean values from 3 mice per group ± S.E.M. Asterisk indicates p < 0.05 as determined by 
a two-tailed Student’s t-test.  ACR values from 28, 35 wks are extremely elevated (red asterisks) with values of 
78.97+/-0.08 and 85.39+/-0.22 respectively. (C) Urine ACR of the Ercc1-PT-KO compared to gGT-cre and Ercc1-/c 
controls. Data reflect the mean values from 3 mice per group ± S.E.M. Asterisk indicates p < 0.05 as determined by a 
two-tailed Student’s t-test. (D) Glomerular filtration rate (GFR) for the Ercc1-Pod-KO, determined by FITC-inulin 
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clearance from the blood after bolus injection. Data reflect the mean GFR in µL/min/g body weight from 3 animals 
per group ± S.E.M. Asterisk indicates p<0.05 as determined by a two-tailed Student’s t-test. (E) Glomerular filtration 
rate (GFR) for the Ercc1-PT-KO determined by FITC-inulin clearance from the blood after bolus injection. Data 
reflect the mean GFR in µL/min/g body weight from 3 animals per group ± S.E.M. Asterisk indicates p<0.05 as 
determined by a two-tailed Student’s t-test. 
3.4.2 Ultrastructural changes in Podocyte Specific Knock-out Only 
In order to determine whether podocyte injury occurs early in the disease process in the Ercc1-
Pod-KO as it does in the Ercc1-/∆  glomerulus, the ultrastructure at early and late time points was 
examined in the knock-out versus the Pod-cre+/- control. At 6 weeks, as seen in the Ercc1-
/∆  glomerulus, thickening and effacement of podocyte foot processes (arrow) was evident in some 
glomeruli, while others appeared to be normal (Figure 17A). The GBM appeared to be of normal 
thickness, but as observed in the Ercc1-/∆  kidney, it thickened substantially by 7 months of age 
(arrowhead). Very few healthy podocytes were evident and those that remained were 
hypertrophied, with large flattened areas against the GBM (asterisk). There was no observed 
difference in the glomeruli of the Ercc1-PT-KO at 7 months, compared to controls.  
In the Ercc1-/∆  kidney, subsequent tubule necrosis and replacement was evident. This 
could be due to inherent damage due to Ercc1 deficiency, or it could be secondary to podocyte 
injury. In all controls and the Ercc1-PT-KO, some proximal tubules appeared to be healthy with 
basolateral membrane folds containing columns of mitochondria (Figure 17B, arrows) and an 
apical border of microvilli (arrowheads). Other tubules appeared to have increased autolysosomal 
structures and disruption of structure, but this did not lead to decreased GFR or albuminuria. 
Conversely, in the 7 month Ercc1-pod-KO, there was major damage to the tubule ultrastructure 
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compared to control, with scattered mitochondria and lack of membrane folds at the basolateral 
side (arrow), disruption of the apical microvilli, extensive debris in the lumen (asterisk), and 
evidence of many double membrane structures and necrotic tubules (arrowhead). This structural 
data and the functional data in Figure 16 provides evidence that early podocyte injury and 
disruption of the glomerular filtration barrier Ercc1 deficient mice is causing the observed 
proximal tubule injury. In Chapter 2, extensive evidence was provided to show that the Ercc1-
/∆  mouse serves as an accurate model of accelerated kidney aging. The evidence presented here 
with the cell specific knock-outs of Ercc1 leads to the hypothesis that early podocyte injury could 
be responsible for causing kidney disease in natural aging as well.  
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Figure 17. Ultrastructural evidence of podocyte and tubule injury in the Ercc1-pod-KO 
(A) TEM micrographs at 20,000X of 6wks and 7mo Pod-cre +/- control and Ercc1-pod-KO glomeruli, as well as 7mo 
gGT-cre +/- control and Ercc1-PT-KO glomeruli. Normal foot process interdigitation and GBM thickness can be seen 
in all control glomeruli, as well as in the Ercc1-PT-KO. In the 6 wk Ercc1-pod-KO, some glomeruli display effacement 
and thickening of foot processes (arrow), but normal GBM thickness. By 7 months, few healthy glomeruli remained, 
and many podocytes appeared to be hypertrophied, with flattened foot processes (asterisks) and extremely thickened, 
irregular GBM (arrowheads). (B) In control kidneys and the Ercc1-PT-KO, normal basolateral membrane folds and 
organized mitochondria are seen (arrowheads), as well as the apical brush border (arrows).  
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3.4.3 Podocyte knock-out of Ercc1 mirrors age-related cellular changes observed in 
Ercc1-/∆ mouse kidney 
3.4.3.1 Tubule injury is secondary to inherent podocyte damage 
There is much evidence that glomerular injury and proteinuria can cause tubule injury(171), and 
the evidence presented thus far here, leads to the hypothesis that this can also occur during 
accelerated kidney aging. Kidney Injury Molecule-1 (KIM-1) has been well established as a 
marker for proximal tubule injury, and up-regulation of KIM-1 leads to fibrosis(171, 172). In order 
to test the hypothesis that tubule injury occurs subsequent to podocyte injury, immunofluorescence 
for KIM-1 was examined in both Ercc1-/∆  and Ercc1-pod-KO kidneys at 1 month and 4 months 
of age. There was no evidence of KIM-1 at 1 month in either mutant when podocyte injury initially 
occurs, but it was evident by 4 months in tubules, both diffusely and at the apical border (insets), 
as well as increased diffusely in 2 yr old WT kidneys (Figure 18).  
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Figure 18. KIM-1 increase indicates tubule injury after 1 month due to podocyte damage. 
Confocal images at a magnification of 200X, showing 1 mo and 4 mo WT, Ercc1 -/∆, and Ercc1-pod-KO kidneys, as 
well as 26 mo WT. Nephrin (red), KIM-1(green), and nuclei (blue). Higher magnification insets, show KIM-1 channel 
only and highlight KIM-1 increase at apical border in Ercc1 deficient kidneys by 4 months and to a lesser degree in 
old WT. 
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3.4.3.2 Vascular changes, myofibroblast accumulation, and macrophage infiltration is 
caused by Podocyte Ercc1 deficiency  
In the Ercc1-/∆  and naturally aged mouse kidney, ICAM up-regulation, SMA actin-positive cell 
increase, and macrophage infiltration occurs. In order to see if these changes can be caused by 
inherent podocyte damage, the same markers were measured in the Ercc1-pod-KO kidneys using 
immunofluorescence. As in the Ercc1-/∆  kidney, an increase in ICAM expression, both in 
glomerular capillaries (glomerulus labeled with nephrin) and at the tubule brush border, occurs 
early, shown at 6 and 16wks in the Ercc1-pod-KO compared to pod-cre +/- control kidneys (Figure 
19A). ICAM was also measured in 7 mo old Ercc1-pod-KO and 8 mo old Ercc1-PT-KO kidneys 
and their controls (Figure 19B). By 7 mo, in the Ercc1-pod-KO kidney, ICAM expression is not 
as pronounced in the glomerulus (arrows), but is still largely increased in the  tubules. A significant 
disruption of glomerular vascular beds, labeled with PECAM, is evident (arrowhead) at this time. 
No change in ICAM or PECAM is observed in 8 month   Ercc1-PT-KO kidney. 
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Figure 19. Early ICAM increase occurs in Ercc1-pod-KO, but not in Ercc1-PT-KO kidneys 
(A) Confocal images at 600x magnification of 6 wk and 16 wk Ercc1-pod-KO kidneys and their pod-cre +/- controls. 
First row shows glomeruli marked by nephrin (red), ICAM (green), and F-actin (blue). The second row shows the 
nephrin channel only. The third row shows the ICAM channel only to highlight the increase in Ercc1-pod-KO’s. (B) 
Confocal images at 200x of 7 month Ercc1-pod-KO and control, and 8 month Ercc1-PT-KO and control. ICAM 
increase is visible only in Ercc1-pod-KO, with irregular vascular architecture (PECAM).  
 
An increase in SMA-positive cells in the Ercc1-/∆ kidney is observed surrounding the 
glomerulus and within the interstitium by 2 months of age. This is also observed in the old, 
naturally aged mouse.  In the 7mo Ercc1-pod-KO kidney, there is a dramatic increase of SMA+ 
cells, not only surrounding the hypertrophied glomeruli, but also inside of the glomeruli (Figure 
20A, arrows), in the tubulointerstitial space and surrounding injured tubules (Figure 20A, 
arrowheads). These images also highlight the largely dilated tubule space, lined by epithelium, 
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which have lost their brush border and normal epithelium morphology. None of these SMA+ 
increases occur in any of the control age-matched animals, nor do they occur in the 8 month Ercc1-
PT-KO.   
 With natural aging and in the Ercc1-/∆  kidney model of accelerated aging, there is 
extensive macrophage infiltration. In the Ercc1-/∆  kidney, this does not occur until 3 mo of age, 
after podocyte injury, NF-κB activation, and other global kidney changes. Similarly, there is severe 
macrophage infiltration in 7 mo Ercc1-pod-KO kidneys, compared to control. There is no 
significant F480 increase in 8 mo Ercc1-PT-KO kidneys compared to control (Figure 20B). The 
lack of global kidney pathologies or change in function in Ercc1-PT-KO indicates that Ercc1 
deficiency in proximal tubule cells does not likely cause age-related kidney disease.  
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Figure 20. Dramatic SMA increase and macrophage infiltration at 7 mo in the Ercc1-pod-KO 
(A) Confocal images at 200x magnification, demonstrating a large increase in smooth muscle actin-positive (SMA+) 
cells in 7 mo Ercc1-pod-KO compared to controls and 8 mo Ercc1-PT-KO. SMA increase is evident surrounding and 
within glomeruli (arrows), as well as interstitially and surrounding injured, dilated tubules. (B) Confocal Images at 
400x magnification of F480 staining in 7 mo Ercc1-pod-KO and Pod-cre+/- controls, as well as 8 mo Ercc1-PT-KO 
and γ−GT+/- controls.  
 
3.4.3.3  Ercc1 deficiency in podocytes causes autophagy impairment, chronic increase in IKK 
expression and mTOR activation  
Finally, in order to characterize the changes within the glomerulus compared to Ercc1-
/∆  glomeruli and to gain an insight into which cellular processes may be contributing to this injury, 
autophagy markers and IKK-β were examined.  In the Ercc1-pod-KO, as in the Ercc1-
/∆  glomeruli, there is an early increase in LC3 at 6wks of age (Figure 21A), compared to control. 
At this time, p62 levels remain low, demonstrating a functional induction of autophagy. However, 
at 4 months, there is an increase in p62 overall and in puncta in the Ercc1-pod-KO, comparable to 
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that seen in the Ercc1-/∆  glomerulus (Figure 21B). This represents a breakdown in autophagic flux 
that occurs with aging, but in an accelerated manner in the Ercc1 deficient podocyte. By 7 months, 
in the Ercc1-pod-KO, there is an accumulation of large puncta that are both LC3 and p62 positive. 
No significant changes were detected in the 8 month Ercc1-PT-KO compared to its control (Figure 
21C).  
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Figure 21. Early induction of autophagy followed by autophagy impairment in the Ercc1 deficient glomerulus 
(A) Representative confocal image of single glomeruli, highlighting the increase in LC3 at 6wks in the Ercc1-pod-
KO vs. the pod-cre+/- control. (B) Representative confocal images of p62 levels in glomeruli from 6wks and 16wks 
from Ercc1-pod-KO and pod-cre+/- controls. P62 levels remain low at 6wks in the Ercc1-pod-KO and Ercc1-/∆ 
glomerulus, demonstrating effective autophagy induction. P62 levels increase significantly by 4 months, 
demonstrating an impairment in autophagic degradation. (C) First row: Representative confocal images at 200X with 
LC3 (green), p62(red), and nuclei (blue). Arrows indicate significant build-up of LC3 and p62 positive, large puncta 
in glomeruli of 7 mo old Ercc1-pod-KO compared to Pod-cre +/- control. This change was not detected in 8 mo Ercc1-
PT-KO, compared to its gGT-cre+/- control. Second and third row: higher magnification of glomeruli, showing only 
LC3 and p62 channels respectively.  
 Chronic NF-κB activation occurred in the podocytes of the Ercc1-/∆  mouse, as did the 
activator of NF-κB, IKK, at an early age. In order to test the hypothesis that this sustained signaling 
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was a result of inherent podocyte damage, IKK expression in the Ercc1-pod-KO and the Ercc1-
PT-KO was compared to their appropriate control kidneys. IKK levels were increased as early as 
16wks in the Ercc1-pod-KO compared to controls (Figure 22A). At 7 months, IKK levels had 
significantly increased in glomeruli of the Ercc1-pod-KO, often localizing to large puncta 
(arrows). IKK levels did not increase in 8 month Ercc1-PT-KO kidneys compared to their gGT-
cre+/- controls (Figure 22B). Also, as in the Ercc1-/∆  mouse glomeruli, pS6 levels were increased 
in podocytes (arrows) in 7 mo Ercc1-pod-KO’s, but not in 8 mo Ercc1-PT-KO’s, compared to 
control. As stated earlier in this chapter, there is much evidence that IKK can result in increased 
mTOR activation, represented here by pS6 increase, as a result of inhibition of the TSC1 
complex(169). Also, increased mTOR activation can lead to the hypertrophy that is observed in 
the Ercc1-pod-KO glomerulus. At 7 months, there are increased levels of pS6 in the glomerular 
podocytes of the Ercc1-pod-KO (arrows, Figure 22C), but not in the Ercc1-PT-KO, compared to 
controls. Also evident is the increased size of the glomerulus in the Ercc1-pod-KO, compared to 
controls and the 8 month Ercc1-PT-KO (Figure 22C, third row).   
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  Figure 22. Sustained IKK increase and mTOR activation in Ercc1-pod-KO glomeruli 
(A) Representative confocal images of a glomerulus showing IKK-β increase at 16 wks in the Ercc1-pod-KO vs. the 
pod-cre+/- control. (B) Confocal images at 200x stained for IKK-β. First row: IKK-β , red; F-actin, green; nuclei, 
blue. Second row: IKK channel only. Third row: higher mag images of IKK in glomeruli. The increase of IKK-β in 
the glomeruli of Ercc1-pod-KO (red arrows) is highlighted here. No change is seen in the Ercc1-PT-KO compared to 
control.  (C) Confocal images at 200x stained for pS6 to represent mTOR activity. First row:  pS6, red; F-actin, green; 
nuclei, blue. Second row: pS6 channel only. Third row: higher mag images of pS6 in glomeruli, highlighting pS6 
increase in the enlarged glomeruli of the 7 mo Ercc1-pod-KO. 
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3.4.4 Crosstalk between IKK-NF-κB and autophagy systems in normal mouse podocyte 
cell line 
There is abundant evidence of a closely-knit relationship between the IKK-NF-κB signaling 
network and the autophagy network in various tissues and cell types(153-158). As presented in the 
introduction of this chapter, IKK-NF-κB can induce autophagy in some cells, but has also been 
shown to inhibit autophagy in other systems(157). It is clear that the relationship is context- and 
tissue dependent. There is also evidence that all three subunits of IKK are degraded by 
autophagy(154, 155). Little to nothing is known about this relationship in normal or aged 
podocytes. Given the above in vivo data presented thus far, it is possible that podocytes, due to 
accumulated oxidative damage during aging, up-regulate autophagy through IKK(153, 154). 
When autophagic flux is in tact in the healthy podocyte, it would degrade IKK in a negative 
feedback mechanism. However, as damage accumulates and autophagic degradation becomes 
impaired, less IKK would be degraded, likely contributing to chronic NF-κB activation(159). 
Before these hypotheses can be tested in aging, it was first necessary to establish a relationship 
between IKK and autophagy in a normal, differentiated mouse podocyte cell line.  
In a differentiated mouse podocyte cell line, grown for 10 days on a collagen IV substrate, 
autophagic flux studies were performed using 25 µM (27, 173) chloroquine, with and without a 
small molecule IKK inhibitor, IKKi VII.   This cell line contains a mutant SV40 antigen which is 
degraded at 37oC, at which point the cells are no longer “immortalized,” and proceed to 
differentiate over a period of 10-14 days, when they express high levels of podocyte-specific 
markers such as nephrin, as well as high levels of LC3, both in diffuse and punctate staining 
patterns indicating a high level of basal autophagy (Figure 23A). This high level of basal autophagy 
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was demonstrated by chloroquine addition to show build-up of LC3+ autophagosomes and 
autolysosomes (Figure 23B, first row, last panel). In order to see how basal autophagy and 
autophagy induction are affected by IKK inhibition, I examined LC3 staining patterns with and 
without serum (to induce autophagy) in control podocytes or with IKK inhibition for 6 hours. Less 
LC3 was detected in cells with IKK inhibition and this effect was pronounced in cultures with 
serum starvation (Figure 23B, second row). Cell number and overall morphology was not affected 
(as measured with DAPI and F-actin staining, data not shown). These results could indicate that 
autophagy induction in podocytes may in part depend on IKK. In order to demonstrate this further 
and to reduce off-target effects from long-term inhibition, IKK inhibitor was added for only 3 
hours, with and without chloroquine addition for the final 2 hours. Interestingly, there was less 
LC3 in the cytoplasm of cells with IKK inhibition (Figure 23C, first row), but more puncta along 
cell-cell junctions. This LC3 staining at cell-cell junctions was also detected in control cells to a 
lesser extent, independent of cell culture density, as well as in freshly isolated glomeruli, where it 
co-localized with nephrin and F-actin (Appendix D, Figure 26). This is the first report of this 
pattern and could represent a new role for LC-3 in podocytes. Upon the addition of chloroquine, it 
is clear that with IKK inhibition, there is less active autophagy, indicated by significantly less 
build-up of LC3+ vesicles (Figure 23C, row 2).  
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   Figure 23. IKKi inhibition results in less active autophagy in differentiated mouse podocytes 
(A) Mouse podocyte cell line, differentiated for 10 days at 37oC on collagen IV. High nephrin and LC3 expression, 
diffuse and in puncta, demonstrates differentiation and high basal autophagy. (B) First row: Control, differentiated 
podocytes, displaying high levels of LC3 with serum (basal levels) and without serum (6 hrs) to induce autophagy. 
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Addition of 25 µM chloroquine for 2 hours results in LC3-positive puncta build-up, demonstrating high levels of 
active autophagy. Second row: IKK inhibition with 500nM IKKi VII small molecule for 6 hrs results in less LC3 
staining, and significantly less LC3 staining with serum starvation, demonstrating an inhibition of autophagy 
induction. (C) First row: short-term IKK inhibition (3 hrs) results in less cytoplasmic LC3 but more LC3 puncta at 
cell-cell junctions. Second row: 25 µM chloroquine addition for 2 hrs with IKK inhibition results in significantly less 
LC3 puncta build-up, compared to controls, demonstrating significantly less active autophagy with IKK inhibition.  
 
With IKK inhibition in podocytes, there is less active autophagy. Therefore, with increased IKK 
activity, there could be an increase in autophagy. In order to test this hypothesis, the differentiated 
mouse podocytes were transiently transfected with a FLAG-tagged, constitutively active IKK 
mutant, termed IKK-2. Transfected cells displayed NF-κB activation, indicated by nuclear p65 
localization, compared to non-transfected cells (Figure 24A).  Transfected podocytes maintained 
their nephrin expression and displayed significantly increased amounts of IKK protein (Figure 
24B). Transfected cells, labeled for the FLAG-tag, displayed increased LC3 and active autophagy, 
shown by LC3 puncta accumulation after chloroquine treatment (Figure 24C). Interestingly, LC3 
was also localized to distinct spots that resemble focal contacts, as well as cell-cell junctions. The 
podocytes in which IKK was constitutively active took on a different morphology with more F-
actin stress fibers, possible undergoing an actin cytoskeleton rearrangement. The work presented 
here in a differentiated mouse podocyte cell line shows that there is a distinct relationship between 
the IKK/ NF-κB pathway and autophagy in podocytes.  
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Figure 24. IKK increases autophagy in podocytes 
(A) Example of IKK-2, transfected cells labeled with FLAG (green) next to neighboring cells with little to no 
transfection, highlighting p65 nuclear localization (NF-κB activation) with constitutively active IKK. (B) IKK-2 
transfected cells continue to express nephrin (red) and display high levels of IKK-β (blue), compared to cells in which 
IKK has been inhibited. (C) Increased LC3 (red) and puncta accumulation with chloroquine administration in IKK-2 
transfected cells (green), compared to those with decreased IKK activity. 
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3.5 DISCUSSION 
Age-related CKD is a major healthcare problem in the U.S., as well as worldwide. It is imperative 
then to study the contribution of aging in order to identify new therapeutic targets and determine 
appropriate therapies for patients depending on their progression of aging nephropathy. Previously, 
we identified the Ercc1-/∆  mouse as an accurate model of accelerated renal aging and provided 
evidence that DNA damage accumulation can drive the kidney aging process. Podocyte injury and 
albuminuria occurred before tubule injury and other global kidney changes. In this chapter, I have 
determined the time-course and nature of major glomerular changes and how they relate to the 
subsequent loss of kidney structure and function, in order to gain mechanistic information 
concerning renal senescence. For the first, time, I present evidence here that damage accumulation 
in podocytes, rather than proximal tubule cells, causes age-related chronic kidney disease in mice,  
NF-κB has been found to be the major transcription factor in humans and mice most closely 
associated with aging(174, 175), and likely may be causing the subsequent changes such as 
endothelial cell activation, macrophage infiltration, coagulation, and fibrosis in rats(45). Wiggins 
et al identified NF-κB activation in an aging rat model in the glomerulus by chromatin immuno-
precipitation (CHIP) assay. Rats that had extended lifespan by calorie restriction had smaller 
glomeruli than the hypertrophied glomeruli of ad libitum fed rats, less proteinuria, and fewer 
upregulated genes associated with NF-κB activation. In another study, researchers found that 
angiotensin receptor blockers (ARBs) prevented the NF-κB activation seen in aged rat kidneys, 
while also reducing oxidative stress and inflammation(50). Here, we show the time course of 
chronic NF-κB activation in the Ercc1-/∆ mouse model and identify podocytes as the primary cell 
type in which this dis-regulated signaling is occurring. While evidence of initial podocyte injury 
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and autophagy induction occurs before this, the onset of chronic NF-κB activation coincided with 
autophagy impairment, a large increase in ACR, decrease in GFR, and the onset of global kidney 
pathologies.  
Dis-regulated autophagy was found to contribute to the podocyte damage seen in a mouse 
model of Fabry’s disease. ESRD is the leading cause of death in males with Fabry’s disease, and 
there is apparent podocyte injury, proteinuria, hematuria, and hypertension(176). Fabry’s disease 
is X-linked and is due to a deficiency in the lysosomal enzyme, hydrolase α−galactosidase A. 
Knockdown with RNAi technology of this gene product in podocytes, results in accumulation of 
autophagosomes and a decrease in subsequent degradation through the autophagy pathway. With 
aging, there is also a persistent decline in degradation and clearance of mitochondria and other 
damaged organelles and macromolecules(19). It is possible that the same oxidative damage that 
affects autophagic substrates, also eventually damages the degradative machinery itself. Elevated 
ROS induces autophagy, but eventually, the system breaks down as the components become 
defective. In the data presented here, there is evidence of oxidative DNA damage, accumulation 
of LC3 and p62-positive compartments, and this likely contributes to a phenotypic transition in 
the podocyte from a stressed but “coping” state to a permanently injured state, which leads to loss 
of a functional glomerular filtration barrier, as well as NF-κB inflammatory signaling.  
The in vitro work presented here shows that the relationship between IKK-NF-κB and 
autophagy exists and warrants further exploration. One question is how is this cross talk achieved? 
Does IKK affect gene expression and/or post-translational modification of autophagy proteins? Is 
IKK affecting autophagy through the mTOR pathway? Finally, further studies using the podocyte 
cell line MP-1 will help determine whether defective autophagy, achieved by autophagy gene 
knock-down or increased ROS, can cause chronic NF-κB activation. Finally, can we facilitate 
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autophagy impairment and IKK/ NF-κB activation with stable knock-down of Ercc1 in vitro in 
order to better elucidate the mechanism of injury and find effective therapies?  
In the hypothalamus of mice, high autophagy activity was detected, and autophagic decline 
correlated with decreased metabolic activity and obesity and insulin resistance(159). In a mouse 
model with hypothalamic autophagy inhibition, IKK-β protein expression increased, and 
introduction of a brain-specific IKK-β knock-out into the model prevented the obesity and insulin 
resistance changes. Therefore, defective autophagy can cause IKK-β dependent inflammatory 
signaling, which can result in metabolic change in vivo. The evidence presented here, in both in 
the mouse models and in vitro, shows that a similar pathological signaling may be occurring in the 
aging podocyte, which could result in loss of normal kidney structure and function with age.  
The creation and characterization of the podocyte-specific Ercc1 knock-out mouse 
presented here, provides strong evidence that the inherent injury due to accumulated damage in 
the podocyte is directly responsible for the age-related chronic kidney disease that results. 
Although, there was some evidence of ultrastructural damage in tubules seen by EM in the 
proximal tubule-specific knockout, this did not result in any measurable deficit in kidney function, 
nor did it activate any of the pathological changes detected in the accelerated, kidney aging model.   
Podocyte damage due to Ercc1 deficiency causes early induction of IKK and autophagy, as a stress 
response. Ultrastructural studies show GBM thickening and podocyte effacement, followed by a 
functional increase in the ACR above controls by a few months of age. By 7 months, EM studies 
show an extremely thickened GBM, indicating a change in glomerular secretory behavior, and dis-
regulated extracellular matrix maintenance.  Eventually, p62 protein accumulates in LC3-positive 
puncta, indicating an impairment in autophagic flux. Interestingly, mTOR activation also increases 
in the glomerulus, as indicated by increased pS6 protein levels. There is also evidence of proximal 
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tubule injury by increased KIM-1 expression by 4 months, indicating that tubule injury is likely 
secondary to podocyte injury. ICAM upregulation is an early event, as in Ercc1-/∆ mouse model, 
indicating that podocyte stress causes endothelial cell activation early in the process. ICAM 
expression on the apical border of the proximal tubule cell may occur in response to the increased 
protein passing into the filtrate. As in the Ercc1-/∆ mouse model, a large increase in smooth muscle 
actin expression and macrophage infiltration occur, with populations infiltrating the glomerulus, 
as well as virtually every interstitial space.  
Extreme albuminuria develops after 16 weeks and the GFR at 7 months has decreased 
below levels seen in the Ercc1-/∆ mouse model. It is important to note that podocytes in the Ercc1-
/∆ mouse model have some Ercc1 protein, whereas the podocytes in the cell-specific knock-out 
have none, likely causing the more extreme kidney phenotype. It will be important to determine 
the extent of knock-out in the podocyte-specific model, as different animals displayed varying 
degrees of severity of structural changes, which correlated to ACR levels. Currently, Ercc1 
antibodies are being tested and laser capture methods are being developed in order to measure 
Ercc1 expression in the glomerulus and other tissues.  Importantly, none of these structural or 
functional changes were detected in the proximal tubule specific knock-out animals. Some damage 
accumulation was seen in autolysosomal-like structures in the tubules of these knock-out animals, 
but this damage did not result in any elevation of the ACR or change in GFR, and there was no 
increase in ICAM or SMA expression, macrophage infiltration, or overt glomerular damage. In 
the Ercc1-/∆ mouse model, proximal tubule cells do show some necrosis and division was detected, 
indicating efficient cell turnover. Perhaps this mechanism is enough to compensate for damaged 
cells while still maintaining kidney function. It will be interesting to study the serum levels of 
sodium, glucose, and other ions to determine whether there is any change in tubule-dependent 
 101 
reabsorption/secretion in the Ercc1 deficient proximal tubule. Additional, the extent of Ercc1 
knock-out in the proximal tubules must be verified.  
With the evidence presented here, it is clear that accumulated DNA and cellular damage 
during aging affects various cell types differently, likely due to each cell’s ability to replace itself 
or degrade damaged material in order to maintain its structure and function. Different cells are 
exposed to varying levels of stress that may cause faster accumulation of damage. The complexly 
differentiated, post-mitotic podocyte is exposed to high levels of distending forces due to 
glomerular blood pressure and not being bound on its apical side. The podocyte is exposed to high 
levels of toxic stress as well and must maintain its complicated architecture, while regulating the 
location and number of slit diaphragms in order to maintain the glomerular filtration barrier. It is 
also responsible for maintaining the GBM and producing growth factors that influence glomerular 
and systemic endothelial cell health. The data herein provide evidence that the glomerular 
podocyte should be a major therapeutic target in age-related CKD. Finding therapies that help 
podocytes maintain or restore autophagic flux, such as ARBs, antioxidants, or factors that renew 
lysosomal degradation, may be key in preventing or regulating NF-κB inflammatory signaling and 
kidney failure that can occur with age.  
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4.0  SUMMARY AND FUTURE DIRECTIONS 
The main goal of this thesis was to introduce a new tool to study kidney aging, and to use this tool 
to address the hypothesis that accumulated unrepaired DNA damage in podocytes causes age-
related kidney disease. I systematically compared the structural, functional, and cellular changes 
that occur in an accelerated manner in the Ercc1 deficient mouse kidney to those of naturally aged 
mice, drawing extremely strong parallels that validate it as tool to study kidney aging in an 
accelerated manner. This work also provides evidence that endogenous DNA damage and plays 
an important role in causing age-related kidney disease, perhaps by activating the DNA damage 
response and NF-κB in the glomerular microenvironment. In addition to this model providing a 
more efficient way of studying aging without confounding factors seen in humans, it also allowed 
us to study the effects of accelerated aging in specific cell types. I demonstrated the Ercc1 
knockout in podocytes was able to cause the same changes in kidney function in a similar 
progression of cellular changes, including tubule injury, endothelial cell activation, macrophage 
infiltration, and fibrosis. A proximal tubule-specific knock-out resulted in some ultrastructural 
changes within the tubules, but no noticeable change in function or cellular changes, as well as no 
impact on lifespan currently (1 year). A significantly decreased lifespan resulted from podocyte-
specific Ercc1 knock-out, providing evidence that renal failure due to podocyte damage may be a 
cause of morbidity in Ercc1 deficient mice. Finally, I demonstrated a correlation between the onset 
of chronic NF-κB activation and autophagy impairment in the podocytes of the progeroid mice. 
My in vitro experiments, for the first time, demonstrate that there is a relationship between IKK/ 
NF-κB and autophagy in podocytes, and that this warrants further study to uncover the mechanism 
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of podocyte injury with aging and to develop and new, targeted therapies to address these 
pathologies.  
I aimed to both quantitatively and qualitatively determine the time-course and progression 
of pathological changes that occurred in the Ercc1-/∆ kidney, compared to changes detected in 2-3 
yr old, naturally aged WT mice. Importantly, analyses of the glomerular transcriptional profiles 
demonstrated strong similarities in gene expression changes between the Ercc1-/∆ kidney and old 
WT, compared to young WT(131).  I determined that podocyte injury and elevated ACR occurs 
before subsequent tubule injury, as detected by KIM-1 protein expression and ultrastructural 
studies. I strengthened my hypothesis that tubule injury was secondary to podocyte injury by 
demonstrating tubule injury in the podocyte-specific knock-out, indicated by Kim-1 staining and 
EM studies. Although EM studies also showed some build-up of lysosomal structures and 
irregularities in the tubules of the proximal tubule specific knock-out, these did not result in the 
increased ICAM expression on the tubules seen in the Ercc1-/∆ or Ercc1-pod-KO, nor did they 
result in KIM-1 expression or changes in kidney function, etc. Therefore, Ercc1 deficiency in the 
proximal tubule is not sufficient to cause any evidence of CKD, and is likely not the primary cause 
of the aging pathologies seen in the Ercc1-/∆ kidney. However, it will be important to further 
characterize the proximal tubule specific knock-out. It is also important to determine whether 
proximal tubule cells in this knock-out animal are turning over in response to injury. Ercc1 
deficiency in proximal tubules could make the kidneys more susceptible to kidney damage with 
systemic disease or acute kidney injury (such as cisplatin or ischemia-reperfusion induced), and 
this would be an interesting and relevant hypothesis to explore.  
I observed an early increase in ICAM in both the podocyte-specific knock-out and in the 
Ercc1-/ mouse, indicating that podocyte injury likely causes vascular changes early in the disease 
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process. It would be interesting to determine the extent of endothelial cell damage that results, as 
well as the extent and progression of vascular dysfunction and rarefaction. An endothelial cell 
specific knock-out of Ercc1 will serve as a valuable tool to determine whether vascular aging can 
cause glomerular injury. Durik et al found evidence of age-related vascular dysfunction in the 
Ercc1-/∆ mouse model by 8 weeks, including arterial stiffness, accelerated vasodilator dysfunction, 
and a slight yet significant rise in blood pressure compared to WT littermates(177). Could an 
endothelial cell specific knock-out recapitulate these changes? Or, perhaps a podocyte-specific 
knock-out could cause age-related vascular dysfunction. These experiments, currently in 
development, could provide extremely valuable knowledge as to whether renal aging can cause 
systemic disease, as well as disease in other organ systems.  
IKK increase and chronic NF-κB activation in the podocytes of Ercc1 deficient mice also 
parallels that seen in naturally aged mice. There is evidence that NF-κB activation with aging, 
causes some of the age-related pathologies in multiple tissues, and inhibition can delay some age-
related conditions(168, 178). Additionally, NF-κB activation can cause ICAM gene expression, as 
well as many other genes seen in kidney aging(32). The data in this thesis show that NF-κB 
activation occurs after initial detection of albuminuria and podocyte injury. While NF-κB 
inhibition may prevent some of the subsequent inflammatory changes seen with aging, it may not 
reverse podocyte injury or loss. This would be an interesting area to explore with the kidney 
relevant Ercc1 deficient mouse models.  Timing and titration of NF-κB inhibition would likely be 
important.  It may be necessary to address the cause of podocyte stress and injury that results in 
this dis-regulated, chronic NF-κB activation, in order to prevent a decrease in kidney function with 
age.  
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One of the first changes detected in podocytes by immunofluorescence was IKK increase 
and LC3 increase in the Ercc1-/∆ mouse and the podocyte specific knock out. At this same time, at 
approximately 1 month, ACR becomes slightly elevated and ultrastructural irregularities were 
detected in podocytes by EM. IKK induction also occurs early in the podocyte specific knock-out, 
as well, indicating this is due to inherent podocyte damage. The in vitro data presented here 
indicate that perhaps autophagy induction is caused by IKK activation. This data warrants further 
exploration, such as quantification of LC3 and other autophagy proteins with IKK manipulation. 
Additionally, does increased IKK activity induce autophagy protein expression, such as Beclin or 
Ulk-1? Is this NF-κB activation dependent or is it an independent function of IKK as others have 
found(153, 154)? Experiments could be performed with p65 knockdown or deletion in podocytes 
to explore independent effects of IKK on autophagy proteins.  
By 8 wks in the Ercc1-/∆ kidney, although LC3 protein levels remain increased, p62 protein 
has also begun to accumulate, indicating the degradation of autophagic substrates is defective. This 
autophagic flux impairment is also detected in the podocyte specific knock-out indicating that this 
impairment is due to inherent podocyte damage; however, further investigation is needed to 
determine time of onset. At this same time in the Ercc1-/∆ kidney, chronic NF-κB activation begins 
specifically in the podocyte. Smooth muscle actin-positive cell populations increase, and 
macrophage infiltration follows by 12 wks. Is the onset of chronic NF-κB activation and autophagy 
impairment related? As discussed, there is evidence that all IKK subunits are degraded by 
autophagy, and autophagic impairment can cause increased levels of IKK(155). Also, defective 
autophagy in the hypothalamus, as an example, can lead to IKK/ NF-κB -dependent changes in 
metabolism that result in obesity in a mouse model(159). In order to address these possibilities in 
podocytes, one could impair autophagy in the differentiated mouse podocyte cell line using 
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chloroquine or 3-MA, or by utilizing genetic knock-down of an autophagy protein, and 
determining whether IKK/ NF-κB activation occurs. Relevant to this aging model, it would be 
interesting to create a stable knock-down of Ercc1 to explore whether it eventually leads to chronic 
NF-κB activation and autophagy impairment, in order to tease out mechanistic details of the cross-
talk between the two pathways with long-term Ercc1 deficiency.  
In order to more effectively bridge the gap between the in vitro and in vivo experiments 
presented in this thesis, I would suggest extending the glomerular isolation and autophagy 
experimental protocol I developed for the experiment presented in Figure 24 of Appendix C. 
Ideally, one could isolate glomeruli from a 1 month old eGFP- NF-κB; Ercc1-/∆ mouse kidney 
(before chronic NF-κB activation begins) and a 3 month eGFP- NF-κB; Ercc1-/∆ mouse kidney 
(when chronic NF-κB activation is at its peak in the glomerulus) to do autophagic flux assays. 
Autophagic flux should be in tact at 1 month, but become impaired in 3 month, eGFP+ podocytes.  
It may also be useful here to explore autophagic flux using high-speed confocal imaging, in young 
and old, isolated glomeruli from transgenic RFP-LC3 mouse kidneys. Additionally, one could 
inhibit autophagy in the 1 month old Ercc1-/∆ isolated glomeruli as well as in young WT glomeruli 
to see if IKK protein increases or NF-κB activation results. Finally, in autophagy-deficient mice, 
is there accelerated chronic NF-κB activation as I have shown here with aging?  
In this thesis, I have presented a new, efficient way of studying the kidney aging process, 
without other confounding factors. Using this model, I have shown that damage accumulation in 
the glomerular podocyte, but not the proximal tubule, is sufficient to cause aging nephropathy. 
Ideally, this model can be used to identify new therapies or suggest prophylactic measures to 
maintain glomerular health in the face of the inevitability of aging. This could be achieved by NF-
κB inhibition, but I hypothesize that the cause of podocyte injury that results in dis-regulation of 
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NF-κB and autophagy impairment must be addressed. It would be interesting to treat the mice with 
an angiotensin receptor blocker (ARB) to look for prevention and reversal of disease. In fact, the 
ARB, losartan, has been shown to inhibit NF-κB -induced inflammatory responses in naturally-
aged rat kidneys, whereby decreasing oxidative damage(50, 179). ARBs are also used to treat 
patients with albuminuria, and there is evidence that they can prevent or lessen podocyte injury in 
diabetic nephropathy animal models. In fact, Angiotensin receptor 1 (ATR1) deficient mice live 
longer, and have lower levels of oxidative stress in many tissues(95). Angiotensin II induces 
autophagy in podocytes, which can be inhibited with antioxidants. In addition to being localized 
on the cell membrane, ATR1 is active on the mitochondrial membrane, and there is evidence that 
AT1 blockade can actually protect mitochondria from damage in experimental diabetes 
models(180). The podocyte specific knock-out of Ercc1 presented here would be a very valuable 
tool with which to study the effectiveness and mechanism of action of ARBs in 
preventing/reversing age-related podocyte injury. 
 Finally, in patients where aging nephropathy has progressed to the point of profound 
autophagic flux impairment in the podocyte, it may be necessary to pursue therapies that can renew 
the degradative capacity of the cell, in combination with those that reduce oxidative stress. For 
example, there is evidence that activation of the lysosome/autophagy biogenesis transcription 
factor, TFEB, can have beneficial effects in Parkinson’s disease models(181). There are 
compounds, such as cobalt protoporphyrin (CoPPIX), which activate TFEB and have been shown 
to inhibit NF-κB activation and restore autophagy and lysosome function in cardiac tissue in sepsis 
models(84). These therapies may be beneficial in treating aging nephropathy that has already 
progressed, in order to restore remaining podocyte health and restore kidney function.  
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In this thesis, I tested the hypothesis that DNA damage can drive kidney aging in the Ercc1-
/∆ and I demonstrated that this model serves as a new tool to study the mechanism and progression 
of aging nephropathy. I used the podocyte and proximal tubule specific Ercc1 knock-out mice to 
determine that podocyte injury during aging is responsible for causing the observed pathological 
changes and kidney function decline, which can eventually cause death. Finally, I demonstrated 
that autophagy impairment and chronic NF-κB activation in the aging podocyte may be related 
and provide possible targets for therapeutic discoveries.  
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APPENDIX A 
 
ABBREVIATION 
 
DEFINITION 
ACR Albumin creatinine ratio 
ALP Alkaline phosphatase 
AMPK 5’ adenosine monophosphate-activated kinase 
Ang II Angiotensin II 
ARB Angiotensin receptor blocker 
ATG Autophagy-related protein 
ATR1 Angiotensin II receptor type 1 
Bcl-2 B cell lymphoma 2 
BrdU Bromodeoxyuridine 
BUN Blood urea nitrogen 
CD31 Cluster of differentiation 31 
CD45 Cluster of differentiation 45 
CD68 Cluster of differentiation 68 
CHIP Chromatin immune-precipitation 
CKD Chronic kidney disease 
COFS Cerebro-oculo facioskeletal 
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CoPPIX Cobalt protoporphyrin 
CPD Cyclopyrimidine dimer 
cPu Cyclopurine 
CR Calorie restriction 
CS Cockayne syndrome 
DAPI 4',6-diamidino-2-phenylindole 
DSB Double strand breaks 
eGFR Estimated glomerular filtration rate 
Ercc1 Excision repair cross-complementary group 1 
ESRD End stage renal disease 
FGF23 Fibroblast growth factor 23 
FITC Fluorescein isothiocynate 
g-GT Gamma-glutamyl transferase 
GBM Glomerular basement membrane 
GFP Green fluorescent protein 
GFR Glomerular filtration rate 
GH Growth hormone 
gH2AX Gamma histone family 2A, member X 
H&E Haematoxylin and eosin 
HRP Horseradish peroxidase 
ICAM Intracellular adhesion molecule 
ICL Interstrand crosslinks 
IFN-γ Interferon gamma 
IGF-1 Insulin-like growth factor 1 
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IHC Immunohistochemistry 
IKK Inhibitor of kappa B kinase 
KIM-1 Kidney injury molecule 1 
LAMP-2 Lysosomal-associated membrane protein 2 
LC3 Light chain-3 
LPS lipopolysaccharide 
mTOR Mammalian target of rapamycin 
NER Nucleotide excision repair 
NF-κB Nuclear factor light-chain-enhancer of activated B cells 
p62 Also called sequestosome-1  
PAS Periodic acid-Schiff 
PBS Phosphate buffered saline 
PECAM Platelet endothelial cell adhesion molecule 
PT Proximal tubule 
RA Renin-angiotensin 
ROS Reactive oxygen species 
SA-β−gal SA-β−galactosidase 
SASP Senescence-associated secretory phenotype 
SIRT1 Sirtuin 1 
SMA Smooth muscle actin 
TASCC Tor-associated spatial coupling compartment 
TBM Tubular basement membrane 
TFEB Transcription factor EB 
TRPV-5 Transient receptor potential vallinoid-5 
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TSC1 Tuberous sclerosis 1 
TUNEL Terminal deoxynucleotidyl  dUTP nick ending labeling 
ULK-1 Unc-51-like kinase 1 
VEGF Vascular endothelial growth factor 
WGA Wheat germ agglutinin 
WT Wild-type 
XP Xeroderma pigmentosum 
XPF Xeroderma pigmentosum group F 
3-MA 3-methyladenine 
Table 4. List of abbreviations  
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APPENDIX B 
 
 
 
Figure 25. Quantification of Podocyte Pedicel and GBM Thickening with Age 
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Foot process (pedicel) thickness was measured in TEM images as the width of the pedicel abutting the basement 
membrane. Only images were used in which a complete cross section of the glomerulus was captured. The data 
represent 3 mice per age and genotype, a minimum of 4 glomeruli and ≥50 pedicels measured per mouse. Each box 
represents an individual mouse, where the top is the first quartile, the bottom is the third quartile and the band in the 
middle equals the median. The whiskers represent the most extreme point no more than 1.5 interquartile range. The 
plots illustrate increasing thickness as well as variability with age. GBM thickness was measured in TEM images as 
the distance between the foot process attachment and the endothelial cell fenestrate. The data represent 3 mice per age 
and genotype, a minimum of 4 glomeruli and ≥40 measurements per mouse.  
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APPENDIX C 
SUPPLEMENTARY TABLE 1:  
Gene Symbol Gene description 
Entrez Gene 
ID 
Affymetrix 
Transcripts Cluster 
Id 
Fold change 
(Ercc1 14 
wks/ WT 14 
wks) 
p-value 
(Ercc1 14 
wks vs.  WT 
14 wks) 
Fold 
change 
(WT 96 
wks/ WT 
14 wks) 
p-value 
(WT 96 wks 
vs.  WT 14 
wks) 
Aldh1a1 
aldehyde 
dehydrogenase 
family 1, subfamily 
A1 11668/// 10461979 6.02 8.52E-07 2.34 3.37E-05 
S100g 
S100 calcium 
binding protein G 12309/// 10607705 4.84 1.41E-02 2.98 4.72E-02 
Gp49a glycoprotein 49 A 14727/// 10363070 3.87 3.96E-03 4.06 2.35E-03 
Calb1 calbindin 1 12307/// 10503416 3.53 4.31E-02 3.26 4.09E-02 
Mt2 metallothionein 2 17750/// 10574023 2.89 1.07E-02 1.76 4.10E-03 
Cdkn1a 
cyclin-dependent 
kinase inhibitor 1A 
(P21) 12575/// 10443463 2.76 7.29E-04 1.50 1.70E-02 
Epha6 Eph receptor A6 13840/// 10440216 2.70 2.51E-06 2.17 2.06E-05 
Prss23 protease, serine, 23 76453/// 10554814 2.61 2.55E-05 1.98 2.10E-05 
Cxcl13 
chemokine (C-X-C 
motif) ligand 13 55985/// 10523359 2.61 1.29E-03 4.42 6.30E-06 
Ctss cathepsin S 13040/// 10494271 2.32 7.92E-04 3.36 2.86E-04 
   10433431 2.28 1.61E-05 2.38 1.09E-05 
Lilrb4 
leukocyte 
immunoglobulin- 14728/// 10363082 2.26 1.71E-02 3.15 1.30E-03 
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like receptor, 
subfamily B, 
member 4 
Pigr 
polymeric 
immunoglobulin 
receptor 18703/// 10349580 2.25 3.68E-02 2.67 4.79E-03 
Ctsc cathepsin C 13032/// 10554789 2.14 3.47E-03 2.64 3.93E-03 
Gpr65 
G-protein coupled 
receptor 65 14744/// 10397645 2.12 8.26E-03 3.73 1.60E-03 
Prss23 protease, serine, 23 76453/// 10565456 2.12 4.72E-05 1.72 3.35E-04 
    10598081 2.11 2.06E-02 2.12 1.70E-03 
Fyb FYN binding protein 23880/// 10422760 2.11 8.10E-03 3.30 1.23E-03 
Lyz2 lysozyme 2 17105/// 10372648 2.08 3.64E-02 3.88 8.69E-04 
Ptgfr 
prostaglandin F 
receptor 19220/// 10502805 2.03 2.58E-02 1.59 3.29E-02 
Clu clusterin 12759/// 10416057 2.02 3.90E-02 2.16 1.73E-02 
Fam26e 
family with 
sequence similarity 
26, member E 103511/// 10368638 1.99 5.42E-05 1.69 2.07E-05 
   10598079 1.99 3.86E-02 2.07 1.51E-03 
H2-Aa 
histocompatibility 
2, class II antigen A, 
alpha 14960/// 10450154 1.97 5.14E-03 4.11 9.48E-05 
Cybb 
cytochrome b-245, 
beta polypeptide 13058/// 10603551 1.95 6.96E-03 2.69 1.20E-03 
Gdpd2 
glycerophosphodies
ter 
phosphodiesterase 
domain containing 2 71584/// 10601044 1.95 4.59E-04 2.04 2.62E-03 
   10433428 1.93 6.69E-05 2.06 4.94E-05 
Adm adrenomedullin 11535/// 10556297 1.91 3.83E-04 1.54 4.81E-03 
   10598077 1.90 1.37E-02 1.86 2.21E-03 
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Cd68 CD68 antigen 12514/// 10387536 1.88 1.52E-03 2.61 1.17E-03 
C3ar1 
complement 
component 3a 
receptor 1 12267/// 10547657 1.87 2.94E-03 2.26 1.19E-02 
Mpeg1 
macrophage 
expressed gene 1 17476/// 10461721 1.86 7.52E-03 2.54 1.67E-03 
Hpgds 
hematopoietic 
prostaglandin D 
synthase 54486/// 10545101 1.86 8.47E-05 1.92 2.04E-03 
   10598071 1.86 1.92E-02 2.26 9.10E-04 
   10598023 1.85 5.84E-03 1.68 1.73E-03 
   10598075 1.82 3.21E-02 2.12 1.29E-03 
Cyp1b1|170003
8P13Rik 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 | 
RIKEN cDNA 
1700038P13 gene 
13078///7326
5/// 10453057 1.78 1.92E-04 1.72 4.68E-06 
Ms4a6c 
membrane-
spanning 4-
domains, subfamily 
A, member 6C 73656/// 10461614 1.75 1.47E-02 1.95 7.39E-03 
Cd74 
CD74 antigen 
(invariant 
polypeptide of 
major 
histocompatibility 
complex, class II 
antigen-associated) 16149/// 10456005 1.74 2.94E-03 3.07 3.27E-04 
   10598053 1.72 1.33E-02 1.72 3.63E-03 
Trim30d 
tripartite motif-
containing 30D 209387/// 10566366 1.71 1.49E-03 1.97 1.30E-04 
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Plbd1 
phospholipase B 
domain containing 1 66857/// 10548817 1.68 4.42E-03 2.15 3.08E-04 
Ly86 
lymphocyte antigen 
86 17084/// 10404606 1.67 5.26E-04 2.26 2.44E-03 
H2-Ab1 
histocompatibility 
2, class II antigen A, 
beta 1 14961/// 10444291 1.65 1.85E-02 3.04 3.69E-04 
Spink8 
serine peptidase 
inhibitor, Kazal type 
8 78709/// 10589407 1.64 2.78E-02 1.65 4.23E-03 
Cd209a CD209a antigen 170786/// 10576784 1.64 8.35E-03 1.76 1.21E-03 
Ccr2 
chemokine (C-C 
motif) receptor 2 12772/// 10590631 1.63 5.35E-03 1.76 2.32E-03 
   10598041 1.62 1.70E-02 1.84 1.06E-03 
Tyrobp 
TYRO protein 
tyrosine kinase 
binding protein 22177/// 10551883 1.61 5.37E-03 2.76 1.19E-03 
C1qc 
complement 
component 1, q 
subcomponent, C 
chain 12262/// 10517513 1.61 3.15E-03 3.19 1.82E-03 
Dcn decorin 13179/// 10365974 1.60 8.26E-03 1.76 1.39E-02 
Msr1 
macrophage 
scavenger receptor 
1 20288/// 10578264 1.58 6.92E-03 1.82 4.66E-03 
Luzp2 
leucine zipper 
protein 2 233271/// 10553537 1.58 8.96E-03 4.07 2.09E-06 
Pilra 
paired 
immunoglobin-like 
type 2 receptor 
alpha 231805/// 10534927 1.57 1.78E-02 2.04 2.49E-03 
   10598032 1.55 4.08E-02 1.71 2.10E-03 
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   10598064 1.55 3.03E-02 1.58 4.66E-03 
Ptprc 
protein tyrosine 
phosphatase, 
receptor type, C 19264/// 10358224 1.55 9.63E-03 2.16 6.53E-03 
Stap1 
signal transducing 
adaptor family 
member 1 56792/// 10522788 1.54 1.32E-02 1.66 1.50E-02 
Mmp12 
matrix 
metallopeptidase 
12 17381/// 10583056 1.54 3.42E-02 2.40 4.09E-03 
Lcp1 
lymphocyte 
cytosolic protein 1 18826/// 10416437 1.54 1.77E-02 2.07 5.18E-03 
Stk17b 
serine/threonine 
kinase 17b 
(apoptosis-
inducing) 98267/// 10354588 1.53 2.05E-03 1.54 3.16E-03 
Clec4a3 
C-type lectin 
domain family 4, 
member a3 73149/// 10541564 1.51 2.66E-02 2.10 8.39E-03 
Table 5. Gene information from transcriptional analysis of Ercc1-/∆ and WT kidneys(131) 
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APPENDIX D 
 
Figure 26. LC3 puncta at cell-cell junctions in podocytes. 
First row: LC3 present at cell-cell junctions, independent of cell density in differentiated mouse podocyte cell line. 
Second row: LC3-present at cell-cell junctions, co-localizing with nephrin and F-actin in podocytes from freshly 
isolated mouse glomeruli (8 wk old mice).  
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APPENDIX E 
Figure 27. Accumulation of LC3+p62+ puncta, decreased autophagy in isolated glomeruli from old WT mice 
Glomeruli were isolated from 5 month WT and 2.5 yr WT mice and cultured overnight on collage IV with or without 
5nM balifomycin. 5 month WT glomeruli displayed high levels of LC3, both diffusely and in puncta and p62 localized 
diffusely and in few puncta. LC3+p62+ puncta accumulated with balifomycin, indicating active autophagy. Glomeruli 
from old WT mice displayed an accumulation of the LC3+p62+ puncta and no additional accumulation with 
bafilomycin, indicating impaired autophagy.  
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